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ABSTRACT 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease (AD). The quest for better therapies to modify the progression of PD is 
still ongoing. During the last two decades, the concept of the etiological basis of PD has 
changed, which has been driven by genetics, the recognition of familial forms, knowledge of 
the effects of the environment and toxins, and genome-wide association studies. Although 
most cases are sporadic, approximately 5–10% of PD cases are due to genetic mutations that 
give rise to the familial forms. Studies using neurotoxins and also genetic mutations that 
underlie familial PD have implicated mitochondrial dysfunction in the pathogenesis of PD. 
Among the different genes associated with familial PD, PTEN-induced putative kinase1 
(Pink1), responsible for the autosomal recessive type, is strongly linked to the mitochondria.  
To investigate in depth the underlying mechanisms of Pink1, we inhibited the function of 
pink1 in zebrafish using morpholino oligonucleotides (MOs). The MO was first thoroughly 
characterized with all necessary control experiments to avoid unspecific effects. Since the 
dopaminergic system is affected in PD, a marker for dopamine, tyrosine hydroxylase (TH), 
was used to assess damage to the system. Due to a genome duplication event that occurred 
early in the evolution of teleosts after the divergence from the mammals, two TH non-allelic 
isoforms were identified in zebrafish: th1 and th2. In the pink1 morphants, both the TH gene 
isoforms were altered. With in situ hybridization, the loss of th1 was found in the ventral 
diencephalon (dopaminergic cell groups 5, 6, 11) and th2 was reduced in the caudal 
hypothalamus (cell group 10b). Similar results were obtained with the cell counting method 
for TH1 immunoreactive cells. TH-ir indicated the loss of cells in the pretectum (group 7) 
and the ventral diencephalic cluster represented by cell groups 5,6,11. These pink1 morphants 
were exposed to subeffective doses of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). This amalgamation of the toxin and genetic manipulation caused 
a locomotor deficit and also facilitated the loss of TH-ir in the same cell populations in the 
larval brains as was instigated by pink1 knockdown alone.  
 
To investigate the involvement of pink1 in cell damage, we used a two-color gene 
expression-based microarray and identified a number of genes that were potentially involved 
in the pathogenic mechanism of the disease. After successful data analysis, the changes in 
critical genes were successfully validated by quantitative real-time PCR. The gene expression 
changes in the morphants, identified by the microarray, were rescued by pink1 mRNA 
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injections, suggesting the specific involvement of pink1 in the differentially expressed gene 
regulation. One of the significant findings was HIF signaling, an important pathway affected 
by pink1 knockdown. Individual factors and genes in the same pathway were validated by 
independent methods in the pink1 morphants to reveal whether pink1 affected hif1α or the 
cascade of events in the signaling pathway. Changes in the VEGF transcripts, erythropoiesis, 
and reactive oxygen species were observed, as were other antioxidant system genes, 
including cat and sod2. These pathways may provide new targets for drug development in 
PD.  
 
To study the mechanisms underlying the involvement of pink1 in oxidative stress-mediated 
PD pathology using zebrafish as a tool, we generated a transgenic line, Tg(pink1:EGFP). The 
Tol2 transgenic approach was used to generate Tg(pink1:EGFP) by using the zebrafish pink1 
promoter. Expression of the pink1 transgene was detected in the telencephalon, midbrain, and 
rhombencephalon in the CNS, and in the muscle, heart, and liver among the peripheral 
organs. The transgenic fish line was used to study the effect of oxidative stress. When 
subjected to a low concentration of hydrogen peroxide (H2O2), which had no effect on the 
mortality or phenotype of the fish, the transgenic fish showed an increase in pink1 transgene 
activity in the brain of the larval zebrafish. Oxidative stress-mediated changes in TH 
expression are valuable for PD study. H2O2 administration did not affect the th1 transcript 
levels, but it significantly increased pink1 expression and reduced the th2 transcript levels. 
This transgenic model will be highly useful for drug development and the screening of new 
potential therapeutic approaches as an in vivo model. 
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ABBREVIATIONS 
5-HT    Serotonin 
6-OHDA   6-hydroxydopamine 
AADC/DDC   Aromatic L-amino acid decarboxylase (EC 4.1.1.28) 
AD   Alzheimer’s disease 
ALS   Amyotrophic lateral sclerosis  
ANOVA  Analysis of variance 
Cat   Catalase 
COMT    Catechol O-methyltransferase (EC 2.1.1.6) 
DA     Dopamine 
DAT/dat  Dopamine transporter 
DBH    Dopamine beta hydroxylase (EC 1.14.17.1) 
dpf   Day(s) post-fertilization 
EGFP   Enhanced green fluorescent protein 
EPO   Erythropoietin 
H2O2   Hydrogen Peroxide  
HA   Histamine 
HD    Huntington’s disease  
HDC/hdc  Histidine decarboxylase (EC 4.1.1.22) 
HIF-1/hif-1(a)  Hypoxia inducible factor-1(a) 
hpf    Hour(s) post-fertilization 
ir   Immunoreactivity 
LC   locus coeruleus 
L-DOPA  3,4-dihydroxyphenylalanine 
LGR   L-Glutathione reduced 
LRRK2   Leucine rich repeat kinase 2 
MAO   Monoamine oxidase A, B (EC 1.4.3.4) 
MHB   Mid-hindbrain boundary 
MO, mo  Morpholino oligonucleotides 
MPTP   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mRNA   Messenger RNA 
NA   Noradrenaline 
NAC   N-Acetyl Cysteine 
NAT   Noradrenaline transporter 
PD   Parkinson’s disease 
PFA    Paraformaldehyde 
PINK1/ pink1  PTEN induced putative kinase 1 
PTEN   Phosphatase and tensin homolog 
q-RT-PCR  Quantitative real-time polymerase chain reaction 
ROS   Reactive oxygen species 
RT-PCR   Reverse transcriptase PCR 
SNpc   Substantia nigra pars compacta 
SNCA   α-synuclein 
sod2   Superoxide dismutase 2 
TALEN  Transcription activator-like effector nuclease 
TH   Tyrosine hydroxylase (EC 1.14.16.2) 
TRAP   Tremor, rigidity, akinesia and postural instability 
vDC   Ventral diencephalon 
VEGF   Vascular endothelial growth factor 
VMAT 2  Vesicular monoamine transporter 2 
WT   Wild-type 
ZFN    Zinc finger nuclease 
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INTRODUCTION 
Parkinson’s disease (PD) is the second most prevalent age-related neurodegenerative disease 
after Alzheimer’s disease (AD), affecting 1–2% of the world’s population over 60 years of 
age. The discovery of dopamine deterioration in PD by Oleh Hornykiewicz paved the way to 
understanding the neuropathology of the disease progression and finding alternatives for 
prevention and cure [1]. Many studies have suggested that central dopaminergic degeneration 
plays a moderate role in cognitive changes in PD patients, and other neurotransmitters and 
biochemical changes are also affected during disease development [2-4]. 
 
A major breakthrough in PD research was the identification of monogenic familial forms of 
the disease. Presently, they account for 5–10% of all PD cases [5]. The five most common 
PD genes that account for the majority of cases are alpha-synuclein (SNCA) [6], leucine-rich 
repeat kinase 2 (LRRK2) [7], PTEN-induced putative kinase 1 (PINK1) [8], dj-1 [9], and 
parkin [10]. Mutations in PINK1 (PARK6) are the second most common cause of autosomal-
recessive PD after Parkin. An impressive body of literature and experimental data in different 
model systems strongly suggests that mitochondrial dysfunction plays a central role in 
clinically similar, early-onset autosomal recessive PD forms caused by parkin, pink1 and dj-1 
gene mutations. PINK1 is a mitochondrially targeted serine/threonine kinase, which has been 
shown to protect cells against oxidative stress-induced apoptosis. The lack of a working 
mammalian model for PINK1-associated Parkinsonism has limited the scope of translating 
laboratory research to understanding of the mechanisms of human PD. 
 
Catecholaminergic modulatory neurotransmitters play an important role in the pathology of 
PD. Tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, serves 
as a consistent marker for the detection of all catecholaminergic neurons in the brain. Using 
antibodies against TH in many species, the catecholaminergic groups have been characterized 
[11-13]. Animal models have been fruitful in addressing fundamental questions and 
providing new insights into the pathogenesis of the disease. The zebrafish provides a rapid 
and effective means for assessing gene function in the vertebrate nervous system. The 
conversion of genetic and biological knowledge derived from fish systems and associated 
with humans has been faster than for other vertebrate models. Due to genome duplication, 
zebrafish researchers have faced a limitation in detecting all catecholaminergic populations in 
the larval and adult zebrafish. The two separate non-allelic isoforms of tyrosine hydroxylase 
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that exist in other species of fish should be characterized in zebrafish for a comprehensive 
explanation of dopaminergic dysfunction [14]. However, no previous studies have identified 
the second TH gene in zebrafish prior to this investigation [15-17]. 
 
Studies using the neurotoxin MPTP have implicated mitochondrial dysfunction, and PINK1 
is a mitochondrial kinase. Using toxin models based on zebrafish and combining them with 
genetic approaches, we have worked towards developing a progressive disease model. The 
goal is to develop an approach in which both contributing components are present. Through 
the combination of both models, we aim to recapitulate essential aspects of the complexity of 
PD, which could contribute towards understanding the etiology of the disease. 
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REVIEW OF THE LITERATURE	  
1. Parkinson’s disease 
The World Health Organization has estimated that neurological disorders hamper one in 
seven people worldwide, an impact that cannot be ignored. The second most prevalent 
neurodegenerative disease after Alzheimer’s disease (AD), affecting nearly 1% of world’s 
population, is Parkinson’s disease (PD). It is an age-related movement disorder, and while 5–
10% of the cases are considered as early onset (occurring earlier than 50 years of age), the 
average age of onset of PD is around 60 years globally [18]. The prevalence of the disease 
increases as a function of age, reaching 4% of the world’s population in the highest age 
group. The nature, symptoms and treatment of PD are of ancient origin, but the true picture of 
the disease only came to light after the symptoms were documented in a monograph entitled 
An essay on the shaking palsy by Sir James Parkinson in 1817 [19, 20]. Earlier, it was known 
as paralysis agitans, and the name “Parkinson’s disease” was coined by Jean-Martin Charcot. 
The underlying biochemical changes in the brain were identified in the 1950s, largely in the 
work of Arvid Carlsson, who discovered that dopamine acts as a neurochemical transmitter in 
the brain [1,21]. The steady and progressive loss of dopamine neurons with age in the 
substantia nigra pars compacta (SNpc) is the main pathological characteristic of PD, along 
with the presence of insoluble protein inclusions termed Lewy bodies [22]. Besides these, the 
characteristic motor symptoms include tremor, rigidity, slowness of movement (akinesia), 
and postural instability, coined as the fundamental signs in the abbreviated form of TRAP 
[23]. 
 
The non-motor symptoms include autonomic dysfunction, cognitive and neurobehavioral 
problems, and sensory and sleep disturbances, which precede the motor dysfunction [23,24]. 
Both the motor and non-motor symptoms cause functional disability of varying degrees in PD 
patients that creates a complex and heterogeneous clinical picture. The non-motor symptoms 
in PD have also transformed the concept of the disease. The etiology of the disease still 
remains a mystery, but it is hypothesized that it may result from a complex interaction 
between environmental factors, genetic susceptibility, and ageing [24]. 
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1.1. Genetics of PD 
Parkinson's disease (PD) is classified into ‘familial’ or early-onset PD (<10% of all patients) 
and idiopathic or late-onset PD (>85% of all cases), which does not appear to exhibit 
heritability [25]. In 1996, the first genetic locus was identified in an Italian descendent with 
pathologically confirmed PD [26]. This study paved way for the modern genetic 
understanding that PD may be hereditary. Nearly 15 years later, a major breakthrough in PD 
research was achieved by the identification of monogenetic variants, which account for up to 
<10% of all PD cases [24]. Many mutations that are responsible for and cause the disease in 
humans have been identified, and many genetic loci have been mapped by genome-wide 
studies that alter the risk for PD, as listed in Table 1 [28-30]. Most PD cases are sporadic, but 
10% of the cases report a family history. The genes show both dominant and recessive modes 
of inheritance. In the last few years, around 18 susceptibility gene loci have been identified 
by genome-wide studies and linkage analysis [27, 29]. So far, five validated PARK genes 
have conclusively been linked to PD [5, 30]. The autosomal dominant PD (ADPD) genes 
include SNCA (PARK1 and 4) and LRRK2 (PARK8). Autosomal recessive PD (ARPD) 
consists of genes such as PINK1 (PARK6), DJ-1 (PARK7), and parkin (PARK2). These 
genetic findings have helped immensely in understanding PD mechanisms at molecular and 
cellular levels using many different cell-based and animal models. 
Table 1. Summary of all PARK-designated loci underlying monogenic PD [28-30].  
EOPD – Early-onset PD; LOPD – Late-onset PD 
PARK loci/Genes Position Inheritance type of Parkinsonism Validated loci/genes 
PD associated loci with conclusive evidence 
PARK1/PARK4/SNCA 4q21 Dominant, rarely sporadic EOPD 
PARK2/parkin 6q25-q27 Recessive; sporadic Juvenile and EOPD 
PARK6/PINK1 1p35-p36 Recessive EOPD 
PARK7/DJ-1 1p36 Recessive EOPD 
PARK8/LRRK2 12q12 Dominant; sporadic LOPD 
Putative loci/genes 
PARK3/Unknown 2p13 Dominant LOPD 
PARK5/UCHL1 4p14 Dominant LOPD 
PARK9/ATP13A2 1p36 Recessive Kuffor-Rakeb syndrome 
PARK17/ VPS35 16q11.2 Dominant;sporadic LOPD 
PARK10/Unknown 1p32 Unclear LOPD 
PARK11/ GIGYF2 2q36-q37 Dominant LOPD 
PARK12/Unknown Xq21-q25 Unclear Not clear 
PARK13/Omi/HTRA2 2p12 Unclear Not clear 
PARK14/PLA2G6 22qq13.1 Recessive EO dystonia-parkinsonism 
PARK15/FBXO7 22q12-q13 Recessive EO parkinsonian pyramidal syndrome 
PARK16 1q32 Unclear LOPD 
PARK18/EIF4G1 3q27.1 Unclear LOPD 
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1.1.1 Autosomal dominant PD genes 
A. SNCA (α- synuclein, PARK1-4) 
The gene α-synuclein was identified in 1994 in the human brain, and the 140 kD amino-acid 
protein was found to be identical to the precursor of the non-Aβ component of Alzheimer's 
disease amyloid [31]. It was the first causative gene to be linked with PD and was found from 
a study on an Italian related family and three non-related Greek descendants [6]. A study 
soon after this finding confirmed that α-synuclein is a major component of Lewy bodies, and 
a pathological hallmark of the disease [32]. Patients with point mutations in this gene had 
dementia and an earlier onset than sporadic cases of PD [32]. 
 
Duplications and triplications of the locus containing this gene suggest that overexpression of 
α-synuclein is toxic and is a major cause of the disease [33]. The intrinsic instability in the α-
synuclein gene locus suggests that the genomic multiplications are de novo, since the 
duplication and triplication events in different PD families have different allele sizes in the 
4q21-23 region [34]. The age of onset, severity of dementia and psychiatric problems appear 
to be associated with the number of copies of the SNCA gene. These findings have led to a 
simplified hypothesis of a linear dose relationship between α-synuclein levels and the severity 
of the disease [5]. Knowledge of most toxic levels of α-synuclein and the structural basis of 
aggregation are crucial for a better diagnosis and prognosis, and for developing effective 
therapies in PD. 
B. Leucine-rich repeat kinase 2 (LRRK2, dardarin, PARK8) 
In 2002, linkage analysis studies in a Japanese family with ADPD led to the discovery of a 
new locus in PARK8 [35]. Mutations in LRRK2 are known to be the most common cause of 
ADPD [5, 7]. The gene has 51 exons encoding a very large 285 kDa protein, which contains 
a central catalytic tridomain with GTPase, a kinase enzymatic domain and multiple protein–
protein interaction domains [5]. Three other domains that have also been identified are a 
leucine-rich repeat (LRR), a tyrosine kinase catalytic domain (ankyrin), and a WD40 domain 
[36]. It has been found that mutations in different domains result in variable pathological 
changes. The common feature amongst all the mutations is neuronal loss and gliosis in the 
substantia nigra, along with Lewy bodies in most cases [36]. The LRRK2 mutations constitute 
around 10% of the familial PD cases, with a clear autosomal-dominant inheritance pattern 
[5]. LRRK2 is expressed in the brain, specifically in the cerebral cortex and putamen, and in 
extra-cerebral tissues such as the lungs or heart [7, 36].  
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1.1.2. Autosomal recessive PD genes 
A. Parkin (PARK2)  
The second gene to be identified as a PD gene and the first to be found responsible for ARPD 
was parkin. The parkin gene was first identified in a Japanese kindred with juvenile onset PD 
[10]. A number of small and large structural changes have subsequently been identified in the 
PARK2 locus, which accounts for the majority of early onset cases, depending on the 
population analyzed [5, 29]. Parkin mutations account for 70% of juvenile cases with an age 
of onset <20 years, comprising ~50% of early-onset (≤40 years) familial cases and ~20% of 
early-onset sporadic PD [28, 37]. The typical age of onset is before 40 years of age, and the 
cardinal symptoms of PD TRAP are mild. The patients usually show foot dystonia, 
hyperreflexia, diurnal fluctuations, and early susceptibility to levodopa-induced dyskinesias 
[38]. Pathological characteristics include neuronal loss and gliosis limited to the substantia 
nigra and locus coeruleus, but characteristic Lewy bodies are absent [10]. Recently, studies 
have reported neurofibrillary tangles and Lewy body pathology in some cases [39]. 
 
The parkin gene comprises 12 exons spanning over 1.4 megabases. It encodes a protein of 
465 amino acids possessing a ubiquitin-like domain and a RING-finger motif, and is the 
second largest gene in the human genome [29]. The parkin gene is structurally divided into 
three parts: the amino-terminal Ubl domain, the carboxy-terminal RING box and the linker 
region, which connects the former two segments. The C-terminal RING box region consists 
of three domains termed RING0, RING1, RING2, and an IBR domain for interaction with the 
ubiquitination machinery [40, 41]. The differences in the pathological condition in Parkin 
mutants account for the variability of mutations in different regions of the gene and gene 
function [5]. 
B. PINK1 (Phosphatase and tensin homolog (PTEN)-induced putative kinase 1, PARK6) 
The first direct genetic link between PD and mitochondrial dysfunction was recognized after 
identifying mutations in the genes encoding PINK1 that led to ARPD. PINK1 was first 
identified in expression profiles of cancer cells [42]. In 2004, two homozygous mutations 
were found in the PINK1 gene as a cause of early onset PD [8]. The PINK1 gene encodes a 
581-amino-acid ubiquitous protein, consisting of an N-terminal 34-amino-acid mitochondrial 
targeting motif, a conserved serine–threonine kinase domain (156–509) and a C-terminal 
autoregulatory domain. It exhibits a mitochondrial topology where the N-terminal domain is 
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located inside the mitochondria and the C-terminal domain faces the cytoplasm[43]. The 
majority of the identified mutations are in the kinase domain, indicating the importance of 
PINK1 enzymatic activity in PD pathogenesis [8, 29]. 
 
PINK1 has been found to be the second most frequent causative gene after parkin. The 
frequency of mutations is in the range of 1–9%, with variations across different ethnicities 
[29]. Despite autosomal recessive transmission, 5% of the sporadic early-onset PD cases have 
single heterozygous pink1 mutations [28, 44]. Most of the disease characteristics are similar 
to those in parkin mutants, jointly with the typical TRAP cardinal signs of PD [5, 38, 44]. 
PINK1-linked PD resembles idiopathic PD, as it shows a good response to levodopa, 
frequently levodopa-induced dyskinesias, and rarely dystonia [28]. 
 
PINK1 is expressed ubiquitously, but most abundantly in the brain as well as in peripheral 
tissues such as the heart (especially in the myocardium), skeletal muscle, or testes in humans, 
mice, and rats [8, 42]. Homozygous or compound heterozygous mutations unequivocally 
cause ARPD in this gene. Single heterozygous mutations have been found to be a risk factor 
for developing PD [45]. Current findings have provided interesting evidence that pink1 and 
parkin function in a common pathway in mitochondrial biogenesis [46]. PINK1 binds to and 
phosphorylates parkin, but how it recruits parkin to mitochondria for mitophagy is unclear. 
This has led to some conclusions that mitochondrial quality control is necessary for the 
etiology of the disease [46]. 
C. DJ-1 (PARK7) 
DJ-1 was first identified as an oncogene, but later this gene was linked by homozygosity 
mapping to ARPD [9]. The DJ-1 gene contains 8 exons distributed over 24 kb and encodes a 
189-amino-acid protein with a still uncertain function [5, 9]. The PARK7 mutations are quite 
rare, with <1% early onset cases having a typical age of onset in the 20s and 30s [5]. 
 
Research into the putative function is still ongoing. DJ-1 is a redox-sensitive molecular 
chaperone. It regulates redox-dependent kinase signaling pathways and antioxidant gene 
expression by protecting mitochondria against oxidative stress [41]. It seems that DJ-1 is also 
involved in the pink1-parkin pathway in protecting mitochondria from oxidative stress [24]. 
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DJ-1 is rare, even in early-onset PD. The DJ-1 protein has been found to be significantly 
increased and oxidatively damaged in many sporadic cases of PD [24]. 
1.3. Mitochondrial dynamics in PD 
Changes in the number, size, and morphology of brain cells occurring during development 
are also accompanied by structural changes within the mitochondria, the powerhouses of the 
cells. Ever since the finding that exposure to the drug 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) leads to PD, mitochondrial dysfunction has been linked to PD 
pathogenesis. Mitochondrial abnormalities have been identified in the SNc of patients with 
PD. Studies within a decade of the discovery of the monogenic forms of PD have further 
strengthened the link between mitochondria and PD [38, 47, 48].  
 
Knockdown studies on PD genes using different models point to mitochondrial dysfunction. 
α-Synuclein mutant mice exhibit mitochondrial degeneration associated with increased 
mtDNA damage and impaired activity of the electron transport chain complex IV cytochrome 
oxidase [49]. DJ-1 knockdown in cultures, Drosophila, zebrafish and mice sensitizes them to 
oxidative stress and MPTP toxicity [50, 51]. The parkin gene is involved in the autophagic 
clearance of mitochondria in the cell in the diseased state by a process called mitophagy [46]. 
PINK1 resides in the inner mitochondrial membrane space and plays a major role in 
mitochondrial maintenance through the phosphorylation of molecules involved in 
mitochondrial dynamics that project to or are located in the cytoplasm [43, 52]. Recent 
studies on the pink1/parkin pathway have demonstrated direct modulation of the 
mitochondrial fusion-fission machinery, highlighting the importance of these proteins in 
mitochondrial quality control in PD [53]. 
 
Biochemical findings from post-mortem brains and studies on toxin-induced animal models 
have revealed altered mitochondrial function in PD, particularly in complex-I of the electron 
transport chain [54-56]. The toxic products of oxidative damage through the disruption of 
complex-I are free radicals, which damage other key cellular components [57]. Mitochondria 
are the main source of endogenous ROS (reactive oxygen species) [58]. Overwhelming 
production of ROS is evident during oxidative stress, and is also a prominent cause of 
neurodegeneration in PD [49, 59]. To test the hypothesis that mitochondrial dysfunction in 
dopamine neurons can cause a progressive PD phenotype, a MitoPark mouse model was 
	  	  
	  
15	  
designed [60]. In these mice, the mitochondrial transcription factor Tfam is selectively 
removed in midbrain dopamine (DA) neurons. The mice have reduced mtDNA expression 
and a respiratory chain deficiency in midbrain DA neurons. This knockout mice model 
exhibits a Parkinsonian phenotype with adult onset of a slowly progressive impairment of 
motor function accompanied by the formation of intraneuronal inclusions and dopamine 
nerve cell death, and the model is able to replicate the slow and progressive development of 
key PD symptoms. A current literature review of different studies reported a conclusive 
finding that complex-1 alterations lead to aggravated ROS production and/or defective ROS 
removal, resulting in oxidative damage to mitochondrial DNA (mtDNA), proteins, and lipids. 
This, in turn, leads to a viscous cycle of oxidative stress and bioenergetic failure in ageing 
and PD [49]. Several studies have linked mitochondrial dysfunction with PD, but it is still 
debatable whether it is the cause or the effect [47]. 
1.4. Toxin-induced models of PD 
The toxin-induced models used to elucidate the pathophysiological mechanism underlying 
PD have been crucial to the development of therapeutic strategies to treat the motor 
symptoms [48]. The neurotoxins widely used to study PD are 6-OHDA and MPTP [3]. The 
6-OHDA rat model and the MPTP primate model have contributed enormously towards 
translating animal experimentation into clinical practice [48]. Epidemiological investigations 
have enhanced studies on the association of pesticides with PD. Besides MPTP analogs, 
reserpine, paraquat, rotenone, dieldrin, organochlorine, and carbamate derivatives have been 
extensively studied as potential toxic candidates [61, 62]. The neurotoxin compounds that 
produce both reversible and irreversible effects such as reserpine, MPTP, 6-OHDA, paraquat, 
and rotenone have been used effectively. However, recent studies have focused more on the 
toxins MPTP and 6-OHDA to produce PD-related pathology. These studies have been 
difficult to interpret unambiguously. To determine the efficacy of these drugs in causing PD, 
many animal models have been used. These studies have been valuable in proving that these 
compounds can mimic parkinsonian syndrome and could prove beneficial for drug 
development [63].  
1.4.1. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD 
The discovery of MPTP in 1983 as a by-product of the chemical synthesis of a meperidine 
analog, also called synthetic heroin, provided the first proof that an environmental toxin 
could produce parkinsonism in humans [64]. MPTP in animal models also produces similar 
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features of human parkinsonism. Since then, MPTP has indeed been considered as a standard 
for toxin-based animal models of PD for replicating the hallmark of α-synuclein 
accumulation [64]. MPTP works by inhibiting mitochondrial function, which is why it 
provided the first clue that mitochondrial impairment might be important in PD pathogenesis 
[65]. It is highly lipophilic in nature and rapidly crosses the blood–brain barrier. Within a 
minute after MPTP injection, levels of the toxin are detectable in the brain [63]. The 
neurotoxin imparts all the cardinal signs of PD when administered. PD develops gradually 
with age, but develops in days of MPTP administration. Quite curiously, rats are resistant to 
MPTP and mouse strains vary widely in their sensitivity to the toxin [66]. MPTP can be 
administered by systemic injection in all the known animal models, which appears to be a 
technical limitation at times [3]. Only two features have been lacking in the MPTP model of 
PD: characteristic Lewy body inclusions and an effect on the TH activity in the locus 
coeruleus in the brain. The best models to replicate completely the PD-like features of MPTP 
administration are monkeys [63]. However, other models have been used, which have also 
replicated human PD pathology and have proven valuable through the generated data in 
understanding the molecular mechanisms of the disease [17, 59, 61, 63]. 
1.4.2. Mechanism of action of MPTP 
MPTP administered intraperitonealy crosses the blood–brain barrier and is metabolically 
activated to 1-methyl-4-pheny-2,3-dihydropyridinium species (MPDP+) by the enzyme 
monoamine oxidase B (MAO-B) in non-dopaminergic cells [67]. MPDP+ is then oxidized to 
1-methyl-4-phenylpyridinium species (MPP+) and released into the extracellular space [68]. 
MPP+ is subsequently taken up into the dopaminergic neurons by the dopamine transporter 
(DAT) [69]. After MPP+ enters the dopaminergic neurons, it is accumulated in the vesicular 
monoamine transporter (VMAT2). VMAT2 ensures a neuroprotective effect through the 
sequestration of MPP+, so that less free MPP+ is available to be accumulated from the cytosol 
into the mitochondria. This was verified when mice expressing reduced levels of VMAT2 
were found more sensitive to MPTP-induced damage at the nigrostriatal DA terminals [70]. 
Once inside mitochondria, MPP+ in turn inhibits the activity of NADH dehydrogenase, which 
blocks the electron flow in the respiratory chain and impairs the cellular supply of energy in 
the form of ATP [71]. The impairment in the respiratory chain is mediated by complex-1, 
which suggests that MPP+ would be lethal to any cell type that depends on aerobic respiration 
[72]. The association of MPP+ with complex-1 is capable of generating ROS, which creates 
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oxidative stress and damages the dopamine homeostasis [48, 63]. Understanding of the 
mechanism by which MPTP kills cells will aid in finding important cues concerning the 
molecular events in PD pathology. 
2.  Modulatory neurotransmitter systems 
The basic unit of the brain, the neuron, was discovered by Santiago Ramon y Cajal, who 
stated that nerve cells were discrete entities that communicate with each other by means of 
specialized contacts [73]. A variety of chemical messengers in the brain help the neurons 
communicate and are called neurotransmitters. There are more than 100 different types of 
neurotransmitters in the brain. Neurotransmitters evoke post-synaptic responses by binding to 
receptors and activating other neurotransmitter responses. Modulatory neurotransmitters are 
different from the classical neurotransmitters, because instead of activating fast ion channel 
receptors, they bind to slowly acting metabotropic receptors, which are most often G-protein-
coupled receptors. A modulatory transmitter frequently alters the efficacy of action by other 
transmitters [74, 75]. The neurotransmitters also belong to distinct categories based on their 
size, such as neuropeptides and biogenic amines. Neuropeptides are relatively large 
transmitter molecules composed of 3–36 amino acids, whereas catecholamines and other 
small transmitters are referred to as small molecule neurotransmitters. The main excitatory 
neurotransmitter is the amino acid glutamate, and the main inhibitory neurotransmitter is 
GABA (Υ-aminobutyric acid). Neurotransmitter imbalance results in disorders such as PD, 
AD, and other psychiatric diseases. One of these neurotransmitter dopamine dysfunctions is 
characteristic of PD. PD treatments that focus on the dopaminergic system alone are unable 
to alleviate both motor and non-motor symptoms, particularly those that develop in early 
stages of the disease. Therefore, the development of agents that interact with several of the 
affected neurotransmission systems could prove invaluable for the treatment of this disease.  
2.1. Biogenic amines 
The biogenic amines are small molecule neurotransmitters that regulate many brain 
functions, and are also active in the peripheral nervous system. These amines are formed by 
enzymatic decarboxylation of naturally occurring amino acids. They are involved in a wide 
range of behaviors, and defects in their functions are therefore mostly implicated in 
psychiatric diseases [76]. The five major and well-established biogenic amines, which 
comprise dopamine, noradrenaline, adrenaline, serotonin and histamine, are associated with a 
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wide range of behaviors, cognitive functions, and homeostatic functions in the CNS. They 
even play an important role in brain development [77]. A brief summary of all the 
modulatory neurotransmitter systems is presented in Table 2 below. 
2.1.1. The catecholaminergic system 
The catecholaminergic system has received considerable attention, particularly because of its 
early recognized involvement in neurological disorders such as PD. The catecholaminergic 
system is comprised of dopamine, noradrenaline and adrenaline, which share the catechol 
moiety [78]. Adrenaline (ADR) was the first of these to be identified as a neurotransmitter 
and a hormone by Abel and Crawford in 1897. In 1946, Ulf von Euler discovered that 
noradrenaline (NA) is the neurotransmitter in sympathetic nerves and the precursor of 
adrenaline. Dopamine was first synthesized in 1910 by George Barger and James Ewens and 
was named 3,4-dihydroxyphenylethylamine [77]. Henry Dale proposed the name dopamine 
(DA) after Peter Holtz discovered the enzyme dopa decarboxylase and showed that it 
produced dopamine from levodopa (L-DOPA). In 1958, Arvid Carlsson identified the 
remarkable functionality of DA as a crucial neurotransmitter. That was the discovery of 
reserpine-induced Parkinsonism with reserpine’s brain dopamine-depleting effect and L-
DOPA’s anti-reserpine action [21, 77-79]. 
 
The catecholamines DA, NA and ADR are important transmitters in the regulation of 
physiological processes and the development of neurological, psychiatric, endocrine, and 
cardiovascular diseases. The pathways for their metabolism are well established and clearly 
understood. These catecholamines are synthesized from the amino acid precursor L-tyrosine. 
The primary source of tyrosine is the diet or the hydroxylation of the amino acid 
phenylalanine in the liver. L-tyrosine is converted to dihydroxyphenylalanine (DOPA) by the 
enzyme tyrosine hydroxylase (TH, EC 1.14.16.2) in the adrenal chromaffin cells [80]. TH 
utilizes molecular oxygen and tetrahydrobiopterin to generate DOPA, dihydrobiopterin and 
water. TH is a rate-limiting enzyme, and changes in its gene expression hamper major 
mechanisms in the catecholaminergic system responses. It has been mapped in the brains of 
many species by antibodies against the enzyme [11, 12]. DOPA is converted into DA by a 
nonspecific enzyme, aromatic L-amino acid decarboxylase (AAAD; EC 4.1.1.28) [81]. The 
activity of AAAD depends on the levels of its cofactor, pyridoxal phosphate. Dopamine is 
taken up from the cytoplasm into storage vesicles and converted into NA by dopamine 
	  	  
	  
19	  
hydroxylase (DBH; EC 1.14.17.1), an enzyme found in soluble and membrane-bound forms 
within storage vesicles [82]. DBH activity utilizes copper, ascorbic acid, and molecular 
oxygen. NA is then converted into ADR by the soluble cytoplasmic enzyme 
phenylethanolamine N-methyltransferase (PNMT; EC 2.1.1.28), which uses S-adenosyl 
methionine as the cofactor [83]. Separate populations of adrenal chromaffin cells contain NA 
and ADR as the final products of CA biosynthesis. Following the synthesis of catecholamines 
in the cytoplasm of pre-synaptic terminals, they are loaded into synaptic vesicles via 
vesicular monoamine transporters (VMAT) and released into the synaptic cleft upon the 
arrival of an action potential [84]. The process of catecholamine release is similar in the 
adrenal medulla and sympathetic nerve endings. An increase in membrane permeability to 
sodium initiates a series of events that lead to an influx of calcium. Via exocytosis, the 
contents of catecholamines in the storage vesicles are then released. However, the exact 
mechanism of Ca+2-evoked exocytosis is unclear [78]. 
 
Catecholamines are subjected to chemical degradation by catechol-O-methyltransferase 
(COMT; EC 2.1.1.6) or oxidative deamination by monoamine oxidase (MAO; EC 1.4.3.4) 
[85]. Both neurons and glia contain mitochondrial MAO and cytoplasmic COMT. MAO is a 
mitochondrial flavoprotein located in the outer membrane of presynaptic neurons, and 
COMT is located in the effector cells [83]. In humans, there are two subtypes of MAO 
localized in the liver. The subtype MAO-A has a higher affinity for NA and ADR and is 
highly localized in brain neurons, while MAO-B is responsible for the degradation of DA.  
Dopamine is deaminated to 3,4-dihydroxyphenylacetaldehyde (DOPAL), whereas NA and 
ADR are both deaminated to 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) [86]. These 
aldehyde intermediates exist only transiently and are rapidly metabolized to the 
corresponding glycols by the enzymes aldehyde reductase (AR) and aldehyde dehydrogenase 
(AD). The final end products of DA, NA and ADR are homovanillic acid (HVA), 3-methoxy-
4-hydroxyphenylglycol (MHPG) and vanillylmandelic acid (VMA), respectively [83]. 
 
The turnover of catecholamines, representing ongoing loss and replenishment by synthesis, is 
usually considered to be driven by catecholamine release in response to increased nerve 
impulse activity. Dopamine action in the synaptic cleft is terminated by the reuptake of 
dopamine by the Na+-dependent dopamine co-transporter (DAT) [87]. NA is cleared from the 
synaptic cleft by the Na+-dependent noradrenaline transporter (NAT) [88]. Although no 
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specific transporter for ADR has been identified, NAT is capable of transporting ADR. NAT 
translocates NA about two-fold more effectively than ADR. This explains why sympathetic 
nerves take up NA more efficiently than ADR [78]. 
 
In 1964, catecholaminergic neurons in the CNS were classified into 12 cell groups (A1–A12) 
[89]. Subsequently, other catecholaminergic cell groups (A13–A16, C1–C3) have been 
defined [11, 90]. The NA groups in the brain were classified into seven cell groups (A1–A7) 
and only exist in the pons and medulla oblongata. The ADR nerve fibers and terminals arise 
in the neuronal perikarya located in three adrenergic cell groups (C1–C3 cell groups) of the 
medulla oblongata. A1, A2, A4, and A7 NA cell groups, along with the C1 and C2 ADR cell 
groups, belong to the “ascending catecholaminergic system”. The Na cell groups A5 and A6, 
together with the C3 ADR group, belong to the “descending catecholaminergic system” [78]. 
 
The dopaminergic system in the CNS is organized into three major systems: the 
mesencephalic (A8–A9), diencephalic (A11, A12, A13, A14, A15), and olfactory (A16) DA 
systems. The mesencephalic DA groups are comprised of three systems: the nigrostriatal, 
mesolimbic, and mesocortical systems [91]. Dopaminergic fibers from these cell groups run 
either in well-organized and target-specific bundles or participate in other neuronal pathways 
innervating practically the entire CNS. 
2.1.2. The serotonergic system 
In 1937, a substance found in the enterochromaffin cells of the gut was identified and named 
enteramine by Vittorio Erspamer. The serum vasoconstrictor factor released from platelets 
during blood clotting was isolated and identified as 5-hydroxytryptamine (5-HT) by Rapport, 
Green, and Page [92, 93]. Later on, they coined the term serotonin [94]. About 95% of the 
total estimated body serotonin exists in the gastrointestinal tract [95]. The existence of 
serotonin in brain and the discovery of the hallucinergic drug lysergic acid diethylamide 
(LSD) paved the way for research into the importance of serotonin in mental illness by 
Woolley [96]. Serotonin is a well-known modulator of cognitive and behavioral functions 
such as sleep, sexual urge, anxiety, appetite, temperature regulators, learning, memory, and 
mood. Altered 5-HT signaling results in the etiology of many neurodevelopmental disorders, 
including depression, anxiety, compulsive disorder, schizophrenia, and autism [94, 97]. 
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The neurotransmitter serotonin is synthesized from the dietary amino acid tryptophan. It is 
mediated through a two-step metabolic pathway starting with the hydroxylation of L-
tryptophan (Trp) by tryptophan hydroxylase (TPH: EC 1.14.16.4) to 5-hydroxytryptophan (5-
HTP) [98]. TPH catalyzes the rate-limiting step in the synthesis of serotonin and the initial, 
uncommitted step in the synthesis of melatonin. It is synthesized in the raphe, pineal, enteric 
neurons of the gut, mast cells, platelets, retina, and thyroid. TPH-mediated catalysis requires 
the cofactor ferrous iron, and the co-substrates oxygen and tetrahydrobiopterin (BH4). TPH 
belongs to a superfamily of aromatic amino acid hydroxylases, together with PAH and TH, 
and undergoes decarboxylation by an aromatic L-amino acid decarboxylase (AAAD: EC 
4.1.1.28) [99]. Two isoforms of TPH exist: TPH1 is peripheral in distribution, while TPH2 is 
predominantly expressed in the brain [98, 100]. 
 
The enzyme AAAD is a shared enzyme in both catecholaminergic and serotonergic synthesis 
pathways and can be detected in both types of cells [101]. The loading of 5-HT into synaptic 
vesicles is carried out by VMAT, which is also responsible for other monoamines. The 
synaptic effects are terminated by transport back into nerve terminals with the aid of 
serotonin transporter (SERT) [102]. The transport of 5-HT by SERT is inhibited by anti-
depressants, and these are therefore called selective serotonin re-uptake inhibitors[103]. 
Serotonin in tissues is rapidly metabolized by the activity of MAO. In the kidney and liver, 
MAO and aldehyde dehydrogenase convert 5-HT to 5-hydroxyindole acetic acid (5-HIAA), 
which is excreted in the urine [95]. 
 
The first study on the localization of the serotonergic neurons was conducted using 
histofluorescence techniques, which revealed the preferential location near the midline of the 
brain stem [89]. The innervation pattern was later confirmed by serotonin antibody staining 
[104]. The serotonin neuronal clusters are allocated based on their distribution and projection 
into nine groups, B1–B9. These are further divided into two groups: the rostral group, B5–
B9, confined to the mesencephalon and rostral pons, and the caudal group, B1–B4, extending 
from the caudal pons to the caudal portion of the medulla oblongata [104, 105]. 
2.1.3. The histaminergic system 
One of the first biogenic amines to be found in the brain was histamine. It was first identified 
by Sir Henry Hallett Dale in 1910 in the smooth muscles of the gut as an imidazolethylamine, 
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denoting an amine occurring in tissues [106]. Kwiatkowski detected histamine in the grey 
matter of the brain in 1941 and White demonstrated its formation and catabolic pathway in 
the brain [107]. The presence of histamine in the brain can be confirmed in two major pools: 
in neurons and mast cells [108]. Histamine occurs in cells of neuro-epithelial and 
hematopoietic origin and serves distinct functions, which has important implications for 
gastrointestinal, immune response, cardiovascular, and reproductive functions [107, 109]. 
 
Histamine is synthesized from the amino acid histidine by histidine decarboxylase (HDC; EC 
4.1.1.22) through oxidative decarboxylation [110]. HDC is a pyridoxal 5’-phosphate-
dependent enzyme found in many species and highly conserved across the animal kingdom 
[107, 111]. The limiting step in histamine synthesis is the availability of the precursor 
histidine. Histamine is packed into vesicles and transported by VMAT2 [112]. To date, no 
other transporter specifically for histamine has been discovered. 
 
Histamine is degraded to an inactive form, tele-methylhistamine (t-MHA), mainly by 
histamine N-methyltransferase (HNMT, EC 2.1.1.8) in the brain [113]. Tele-methylhistamine 
is further metabolized to t-methyl-imidazoleacetic acid by monoamine oxidase B and 
aldehyde dehydrogenase [107]. In non-neuronal tissues, histamine is oxidized by diamine 
oxidase (DAO; EC 1.4.3.3) [114]. While many biochemical and electrophysiological studies 
indicating the presence of neuronal histamine had been performed earlier, it was not until the 
development of antibodies against histamine and HDC by two separate research groups that 
the exact localization and projection pattern could be determined [115, 116]. These studies 
demonstrated that the histaminergic neurons are confined to a small region of the posterior 
hypothalamus called the tuberomammillary nucleus (TMN), with widespread projections to 
different regions. There are two ascending pathways and one descending from the TMN 
[115]. All the histaminergic neurons are classified as one group, as they have similar 
projection patterns. Single neurons may even have both ascending and descending axon 
projections [117]. Histamine neurons play an intricate role in many neurodegenerative 
diseases such as AD, PD, schizophrenia, and epilepsy [107, 109]. In AD, the degeneration 
and tangle formation of histaminergic neurons and decline in HDC activity have been noted 
[109]. In the case of PD, an increase in the histamine concentration has been observed [109, 
118]. The modulator role of the histaminergic system becomes prominent in perturbed states 
of disease, but the factors that regulate this function are still unclear. 
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Table 2. Summary of neurotransmitter synthesis, storage, transport, and degradation 
Neurotransmitter Precursor Synthesizing enzymes 
Metabolising 
enzyme Metabolite Transporter 
Noradrenaline 
(NA) 
and 
Adrenaline (A) 
L-tyrosine, 
L-DOPA, 
Dopamine 
Tyrosine 
hydroxylase, L-
aromatic amino-acid 
decarboxylase,  
Dopamine-β-
hydroxylase, 
Phenylethanolamine-
N-methyl transferase 
Monoamine 
oxidase and 
Catechol-O 
methyl 
transferase 
 
Vanillylmande
lic acid 
(VMA) and 3-
methoxy-4-
hydroxy 
phenylglycol 
(MHPG) 
Noradrenaline 
transporter 
Dopamine L-tyrosine, L-DOPA 
Tyrosine 
hydroxylase, DOPA 
decarboxylase 
Monoamine 
oxidase and 
Catechol-O 
methyl 
transferase 
 
3,4-Dihydroxy 
phenylacetic 
acid (DOPAC) 
and 
homovanillic 
acid (HVA) 
Dopamine 
transporter 
5-
Hydroxytryptamine 
(5-HT; serotonin) 
5-hydroxy-
tryptophan 
Tryptophan 
hydroxylase, 5HTP 
decarboxylase 
Monoamine 
oxidase 
5-
Hydroxyindol
eacetic acid 
Serotonin 
transporter 
 
Histamine (HA) L-histidine Histidine decarboxylase 
Histamine-N-
methyl 
transferase 
Telemethyl 
histamine, 
Imidazole 
acetic acid 
Yet to be 
identified 
 
3. Oxidative stress and hypoxia in PD pathology 
A healthy and normal human brain utilizes 20% of the total oxygen taken up by the body, 
which makes oxygen imperative for life. As a major consumer of energy, the brain is 
particularly susceptible to changes in the oxygen conditions [119]. The presence of 
neuromelanin in the dopaminergic cells endures the autoxidation of dopamine, leading to 
semiquinone formation and polymerization, through which radical species are produced 
[120]. The degradation of dopamine by MAO also produces hydrogen peroxide (H2O2), 
which further emphasizes the involvement of oxidative stress. Enzymatic oxidation of 
dopamine to H2O2 has been found to cause the increased formation of oxidized glutathione 
(GSH), suggesting the occurrence of oxidative stress and impairment of a major antioxidant 
system [121]. The occurrence of oxidative stress in PD is supported by both post-mortem 
studies and by studies demonstrating the capacity of oxidative stress and oxidizing toxins to 
induce nigral cell degeneration [57]. 
 
The sensitivity of the nigrostriatal pathway to selective toxins such as MPTP and 6-OHDA 
demonstrates its vulnerability to free radical attack. Mitochondria are the main producers of 
ROS and the main targets of oxidative damage. Mitochondrial ROS are putative signaling 
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molecules between cellular oxygen sensors and hypoxia-inducible factor-1 (HIF-1). HIF-1α, 
a transcription factor, is a master regulator of cellular oxygen homeostasis. HIF-1α regulates 
the expression of a wide range of genes involved in vasomotor control, angiogenesis, 
erythropoiesis, iron metabolism, cell cycle control, cell proliferation and death, and energy 
metabolism [122]. HIF-1α is impaired in PD, as has been found in an MPTP mouse model 
and PC12 cell line study [123]. MPP+ effectively inhibits both complex I activity and the 
hypoxic accumulation of HIF-1α protein in dopaminergic cell lines PC12 and CATH. 
Promoter activity studies on TH have suggested that the TH gene is under the control of a 
hypoxia response element [124]. Knockdown mice for HIF-1α exhibited a 40% decline in TH 
expression in the brain [125]. 
 
Severe and prolonged hypoxia contributes to brain damage because of the exacerbated 
production of reactive oxygen species (ROS), which leads to oxidative stress. Oxidative 
stress, defined as an imbalance between biochemical processes leading to the production of 
reactive oxygen species (ROS) and a defect in the cellular antioxidant cascade, causes 
molecular damage that can lead to the critical failure of biological functions and the death of 
neurons. The contribution of hypoxia and hypoxia-mediated pathways to neurodegeneration 
remains unclear. The beneficial effects of HIF-1 can arise mainly from the increased 
expression of HIF-1 along with its target genes, which can combat oxidative stress, improve 
the blood oxygen and glucose supply, promote glucose metabolism, regulate iron 
homeostasis, activate the synthesis of dopamine, and block cell death signaling pathways. 
Increasing HIF-1 activity may be an important potential strategy for preventing the onset or 
ameliorating the pathogenesis of PD.  
4.	  Zebrafish	  as	  a	  model	  
The zebrafish has emerged as an excellent model organism for studies on vertebrate biology. 
Even though the zebrafish had earlier been used as a model organism, the starting point for 
the contemporary use of zebrafish was in 1970s, when George Streisinger at Oregon 
University selected it for studies on genetics and embryology [126]. 
 
The zebrafish is a small tropical freshwater fish commonly found in Southeast Asia. It 
belongs to the order cypriniformes in the class Actinopterygii. A significant step for the use 
of this organism as a model and in the development of this field was a large mutagenesis 
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screen carried out in the 1990s [127, 128]. Many mutants identified in this screen are 
reminiscent of numerous human diseases and have increased our understanding of human 
biology. The zebrafish has easily distinguishable sexes, as males are torpedo shaped and have 
gold stripes between the blue stripes, while females have a larger, whitish belly and have 
silver stripes instead of gold ones (Figure 1). Therefore, it is easy to set up breeding pairs to 
obtain a large number of progeny. The zebrafish genome has now been completely sequenced 
and assembled with a sequence length of 1.4 Gb in 4560 scaffolds by the Sanger Center 
(http://www.sanger.ac.uk/Projects/D_rerio/Zv9_assembly_information.shtml). This is highly 
beneficial when performing experiments that involve gene manipulations. 
 
Figure 1: Sex determination in zebrafish. The females are larger with silver stripes and males 
are torpedo shaped with gold stripes between the blue stripes. 
4.1. Advantages and disadvantages of zebrafish 
The zebrafish is small vertebrate more closely linked to the human evolutionary lineage than 
the commonly used Drosophila or C. elegans. Zebrafish are easy to maintain, manipulate and 
observe. Females lay a large number of eggs, which are externally fertilized. Their high 
fecundity makes zebrafish an excellent model for genetic screens and analysis. These are 
very robust fish and can tolerate a wide range of temperatures, lighting, and a reasonable 
amount of stress. Because of their small size and short generation time, they are cost efficient 
to maintain in large numbers. The breeding can be timed and easily controlled by changing 
the light–dark cycle. The large number of embryos from a single batch of fish increases the 
statistical significance of the sample sizes for any kind of experiment. Moreover, the ability 
to have a large number of progeny from a single pair makes it easy to map mutations and 
cloned genes up to 0.1 cM in resolution. 
The rapid external development of the embryos facilitates a number of technical 
manipulations such as microinjections, cell transplantations, microsurgery, and cell 
ablations. The transparent embryos are an excellent aid to developmental biologists studying 
the development from a single cell to a larva in 24 hours. The optical clarity and physical 
accessibility of zebrafish embryos make this an ideal system to exploit the advantages of 
	  	  
	  
26	  
transgenic animals expressing fluorescent proteins [129]. By establishing transgenic lines 
under a tissue-specific promoter, it is also possible to label different cell types and visualize 
the expression of genes in real time [130]. 
 
The zebrafish model also has some pitfalls. The eggs develop outside of the body, and while 
there are advantages to this for the purpose of observing embryonic development, there are 
limitations when studying vertebrate maternal behavior or aspects of in utero development. It 
is a vertebrate, but in comparison to the mammals, it lacks specific organ structures such as 
the lungs, prostrate, and bladder [131]. This is due to specialized structures unique to the 
aquatic environment. The biology behind the different aspects of zebrafish behavior has also 
been insufficiently studied. 
4.2. Genetic manipulations 
The application of forward and reverse genetic approaches has helped to define and dissect 
particular pathways or processes without a priori knowledge of genes or their functions 
(Figure 2). Historically, the first forward genetic approach in microorganisms, bacteriophages 
and others helped to decipher the triplet genetic code [132]. Subsequently, it has been applied 
in Caenorhabditis elegans and Drosophila melanogaster, which are invertebrates, and Danio 
rerio, a vertebrate [133, 134]. Zebrafish genetics gained prominence following two large-
scale mutagenesis screens, which provided the basis for the discovery of a multitude of new 
genes and pathways fundamental to vertebrate development [127, 128]. These studies 
exploited an enormous number of mutant strains, many of which were relevant for 
understanding a number of human diseases. The need for complementary reverse genetic 
approaches to enable relatively the straightforward reverse genetic manipulation of genes of 
interest arose. Technological advances have mainly occurred in gene knockdown mediated 
by anti-sense morpholino phosphorodiamidate antisense oligonucleotides (MOs), TILLING 
(Targeting Induced Local Lesions in Genomes), retroviruses, and transposons. Recently, 
mutagenesis and the induction of heritable genetic alterations with ZFNs (zinc finger 
nucleases) and TALENS (transcription activator–like effector nuclease) have opened up a 
new era in zebrafish reverse genetics [134]. Both the forward and reverse genetic methods 
facilitate the detailed study of gene function in development and disease. They have a final 
aim of revolutionizing the way gene function is studied and provide the basis for the 
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discovery of a multitude of new genes and pathways fundamental to vertebrate development. 
A comparison of both the strategies is represented below (Figure 2). 
	  
Figure 2: Comparison of the two different genetic manipulation strategies revealing the 
current technical advantages of using zebrafish to provide important new insights into 
vertebrate development and human disease. 
4.2.1. Forward genetic screens 
The forward genetic approach aims to identify genes involved in a biological pathway or 
process by screening populations of animals that contain random mutations throughout the 
genome that can alter the gene function. This approach has two key requirements: first, a 
well-defined genetic background of the organism, and secondly, a reproducible procedure to 
identify mutants of interest. In zebrafish, several mutagens have been tried and tested for this 
purpose. The initial research, which involved gamma radiation, resulted in large deletions, 
translocations and other gross chromosomal aberrations, which were difficult to identify for a 
mutant phenotype [135]. Alkylating agents, in particular N-ethyl-N-nitrosourea (ENU), were 
identified that could achieve high mutagenic loads, and the phenotypes could be linked to 
lesions in one gene [136]. Since then, ENU has been the standard choice for chemical 
mutagenesis [133]. Insertional mutagenesis by retroviruses has been applied, but with a very 
much lower mutagenic frequency than ENU [137]. In a few subsequent attempts, small-scale 
mutagenesis by transposable elements has also been applied [138]. Despite the significant 
efforts required to perform forward screens in zebrafish, researchers are continuing to 
develop and apply novel screening strategies to explore vertebrate development in greater 
breadth and depth. 
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4.2.2. Reverse genetic screens 
In the reverse genetic approach, a known gene is disrupted to analyze the phenotype of the 
organism to understand the gene function. Due to the large size of the zebrafish genome, and 
also genome duplication, it is quite difficult to identify all relevant genes using forward 
screens alone. This can be achieved by four different methods, as described below. 
A. Morpholino phosphorodiamidate antisense oligonucleotides (MOs) 
The RNAi-mediated knockdown technologies have been problematic in zebrafish, with very 
few successful efforts [139]. Therefore, knockdown of gene function through the use of 
antisense morpholino oligonucleotides (MOs) has gained popularity [140]. The resistance to 
breakdown by nucleases and the ease of binding stably with RNA increases the penetrant 
gene knockdown effects [141]. MOs sequences are designed so that they function by forming 
heteroduplexes with the target transcript to interfere with protein synthesis or splicing by 
binding to the initiation start codon or splice acceptor sequences. MOs are injected into 
freshly fertilized eggs at the one- to two-cell stage to effectively block the gene function until 
5 days post-fertilization (dpf), before becoming diluted to efficiently interfere with gene 
dysfunction [142]. The ease of use and rapid assessment of gene function are the biggest 
advantages of MOs, but proper controls are needed. Careful optimization of the dose and 
observation of the resulting phenotypes for the potential risk of off-target effects are the basis 
of a good MO design to avoid unspecific phenotypes [143]. With the proper controls and 
effective downregulation, MO-based knockdown is one of the most advantageous techniques 
the zebrafish has to offer. 
B. TILLING (targeted induced local lesions in genomes) 
This is a method combining forward and reverse genetics based on ENU-induced chemical 
mutagenesis to isolate mutants harboring point mutations in genes of interest. It was the first 
genetic approach in zebrafish to successfully yield germline mutations in a desired target 
gene. Mutations in target genes are sought by sequencing the target regions from genomes 
extracted from the mutagenized individuals [144]. This method involves a large degree of 
effort and investment. The major drawback of this method is that a mutation of interest that is 
identified in any given F1 fish is only one of many heterozygous mutations in its genome. To 
rule out confounding effects from linked mutations, more than one mutant allele should be 
characterized. Otherwise, mRNA should rescue the phenotype through the expression of a 
wild-type version of the allele or by a transgene. With the development of massively parallel 
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sequencing platforms, new avenues have been provided for rapidly screening TILLING 
libraries, which can dramatically increase the rate of discovery [145].  
C. Retroviral and transposon-mediated mutagenesis 
Insertional mutagenesis by retroviruses or transposons has been utilized to identify modified 
alleles of a target gene [137]. Retroviruses appear to cause mutations in zebrafish by several 
major mechanisms, including exon disruption and gene silencing caused by insertion into an 
intron. Such insertions either lead to a complete loss of the wild-type gene product or the 
reduction or complete abrogation of endogenous RNA expression [146]. This method has 
generated large numbers of genes important for vertebrate development, but the need to use a 
reporter gene, such as GFP, to visualize living embryos has directly emerged. The Tol2-based 
transposon system was developed to efficiently generate transposon insertions in the 
zebrafish genome [147]. Previously, the different methods to create transgenic fish were not 
as efficient as Tol2. The frequency of obtaining a founder fish following the injection of 
naked DNA was 5–9%, while the Tc3 transposon system gave a frequency of 7.5%, 
pseudotyped retrovirus expressing GFP 10%, the I-SceI meganuclease system 30.5%, and the 
sleeping beauty had an efficiency of 5–31% [147]. Together with gateway technology, co-
injection of expression constructs containing transgenes flanked by the Tol2 elements with 
the transposase mRNAs greatly enhances the efficiency of transgenesis in zebrafish, 
including germ line transmission up to 50%, a higher frequency than with any other method 
[148]. This approach is quite useful to study gene function during normal vertebrate 
development and organogenesis. 
D. Zinc finger nucleases (ZFNs) 
The need for effective reverse genetic tools for creating targeted knockouts has been growing 
incessantly. Zinc finger nucleases (ZFNs) showed promise in improving the efficiency of 
gene targeting. ZFNs are engineered restriction enzymes that can be customized to cut a 
DNA sequence of interest. These work by introducing DNA double-strand breaks in target 
genes. This can then stimulate the cell's endogenous homologous recombination machinery 
and create gene modifications during subsequent repair [149]. The application of ZFNs 
against zebrafish genes results in an impressive >25% of offspring with germline 
modification of the exon targeted by the customized gene-specific ZFN [150]. The access to 
customized ZFNs is the current bottleneck in implementing this technique in zebrafish, and 
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the production of validated ZFN pairs is technically challenging and costly. This technology 
needs to be scaled up, and we are still unaware of whether all genes could be targeted by this 
method due to the complexity of DNA-binding domains. The ZFN-binding domain contains 
3 to 4 DNA recognition modules, each of which recognizes 3 DNA bases. When all the 
modules are assembled as one DNA-binding domain, the specificity of DNA binding can 
decrease. Therefore, designing specific ZFN pairs that recognize specific loci of the genome 
is selective, making some genes unavailable for targeted knockout via ZFN [151]. There is a 
growing list of zebrafish lines produced by this method, but the method also has the potential 
risk of causing off-target effects [152]. 
E. Transcription activator-like effector nucleases (TALENS) 
TALENs are based on similar principles as ZFNs and are emerging as new and efficient tools 
for gene-targeted mutagenesis [153]. TALENS use the same functional domains, the 
restriction enzyme domain and the DNA-binding domain. The transcription activator-like 
effector (TALE) sequence-specific DNA-binding domain proteins have been used for gene 
targeting in plant pathogenic bacteria [154]. The mechanism of action is as follows. When 
fused to the FokI nuclease domain (the same nuclease as used in ZFNs), TALE nucleases 
(TALENs) recognize specific DNA sequences using a straightforward DNA base recognition 
cipher. Binding of two TALENs to DNA allows FokI to dimerize and create a targeted 
chromosome break. TALENs can effectively recognize targeted loci in both somatic and 
germline cells in the zebrafish. For sites successfully targeted by ZFNs, TALENs appears 
more effective and readily able to induce cleavage and introduce subsequent mutations [153]. 
A recent paper reports that TALENs have fewer off-targeting issues than ZFNs [155]. Not all 
issues encountered by ZFNs have yet been completely investigated by TALENs. A recent 
advancement in this field has been by the usage of clustered, regularly interspaced, short 
palindromic repeats (CRISPR) along with the Cas protein system for genome editing in the 
zebrafish. The CRISPR-Cas system functions in vivo to induce targeted genetic modifications 
in zebrafish embryos with efficiencies similar to those obtained using zinc finger nucleases 
and transcription activator-like effector nucleases [156]. The efficacy of mutagenesis varies 
dramatically, and more characteristics of this system still need to be investigated [157]. 
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4.3. Zebrafish models of human diseases 
The large-scale mutagenesis screens identified an enormous number of mutants that resemble 
human clinical disorders. The challenges in other systems became an advantage for this fish 
model. Early embryonic study cannot always be re-capitulated in the mice, as they develop in 
utero. Drosophila and Caenorhabditis elegans can serve as powerful model systems for 
many biological processes, but they cannot address the development and function of 
vertebrate-specific features. The rapid progress of the zebrafish genome initiative is bringing 
this model system to its full potential for the study of vertebrate biology, physiology and 
human disease. 
 
The zebrafish has been used to study cardiovascular defects, because the fish embryonic heart 
resembles the heart of the human embryo at three weeks of gestation [158]. Unlike the rodent 
model, the two-chambered heart does not need blood circulation for survival early during 
development. Defects in cardiac development or function are more likely to be recoverable 
and provide the first significant insight into the molecular basis of the defect. The condition 
‘bradycardia’ is mimicked in a mutant slow mo, which has a slow heart rate [159]. The 
zebrafish mutant gridlock resembles the human congenital disorder coarctation of the aorta in 
both the location and effects of the lesion. Heart rate, oxygen consumption, and blood 
pressure have all been assayed in developing wild-type embryos. The blood circulation in 
zebrafish starts as early as 24 hpf, and the number and morphology (of blood vessels?) are 
easily visible under the microscope. This makes it amenable for the study of hematopoiesis 
[160]. The defective mutants can provide a better understanding of normal hematopoietic 
processes, and reveal important clues to the pathophysiology of stem cell disorders and 
leukemia. Many characteristics of kidney development and function in zebrafish are similar 
to those of higher vertebrates, thus providing a simple and accessible system for 
investigation. The zebrafish pronephric kidney is a relatively simple organ, consisting of two 
nephrons with fused glomeruli and paired, bilateral pronephric ducts [161]. Many mutants are 
reminiscent of human autosomal dominant polycystic kidney disorders [162]. As the 
zebrafish homologues of these genes are identified, their function can be dissected. The use 
of zebrafish can also be extended to study other organs such as the eye and brain, and various 
other vertebrate-specific and clinically relevant developmental processes. The implications of 
studies on the brain of zebrafish have been dissected in many neurodegenerative models, 
including PD (discussed below). Using reverse genetics techniques, transgenic fish have been 
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successfully generated, allowing for cell lineage tracing experiments, tissue-specific 
transgene expression, and transplantation studies that will provide invaluable clues to human 
pathophysiology [163]. 
4.4. Zebrafish models of Parkinson’s disease 
Progress in understanding PD pathophysiology and in the development of treatments would 
benefit greatly from improved animal models. Due to the simplicity of zebrafish genetics and 
specific brain regions that are conserved and comparable to human counterparts, it is a good 
model to study the genetics of PD. Orthologs for genes such as pink1, parkin, lrrk2 and dj-1 
responsible for Mendelian PD have been found in zebrafish. These genes have been studied 
by using methodologies such as MO knockdown or transgenic overexpression of mutants. 
 
Recently, pink1 has been studied using C. elegans, in which a reduction in the length of 
mitochondrial cristae was observed. This species showed increased sensitivity to paraquat 
[164]. In the Drosophila pink1 model, mitochondrial deficits leading to the degeneration of 
flight muscles and DA neuron loss have been found [165-167]. These defects were not 
observed in the mouse model, and therefore could not reproduce the human symptoms[168]. 
Some of the observations in mice models also varied due to strain differences. In one of the 
pink1 knockout mice, impaired mitochondrial respiration and increased sensitivity to H2O2 
and MPTP was recorded [169]. This mouse strain also showed heart defects, along with 
impaired dopamine release in the striatum [170]. In another pink1 deficient strain of mice, 
abnormalities in the serotonergic system were associated with gait alteration, and olfactory 
dysfunction was noted [4]. In a zebrafish model for pink1, loss of both the th1 and th2 
transcripts was observed [142]. Some researchers have reported patterning differences and 
projection alteration without a reduction in TH cell numbers [171]. In the pink1 mutant, with 
a mutation in exon 7, no obvious phenotype was observed, but it had reduced numbers of DA 
neurons and reduced mitochondrial complex I activity [172]. In the medaka pink1 mutant, 
there was decrease in dopamine metabolites, but no dopaminergic cell loss was evident. 
Behavioral abnormalities were also observed in the mutants [173]. 
In the parkin model, a 20% loss of DA neurons in the vDC with increased susceptibility to 
MPTP was recorded. Reduced complex I activity similar to parkin patients was noted [54]. In 
the dj-1 model of the zebrafish morphant, reduced DA neurons were not seen, but they were 
more sensitive to H2O2 or to proteasome inhibitor MG132. They were also more susceptible 
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to programmed cell death [50]. The MOs for lrrk2 caused a significant loss of DA neurons in 
the vDC along with locomotor defects similar to human counterparts [174]. Several other loci 
have now been identified as PD susceptibility genes, responsible for rare forms of the disease 
[30]. Two of these have been identified in zebrafish, uchl-1 and GIGYF2 [175, 176]. Thus, 
the zebrafish is a good alternative model in elucidating the molecular basis of human 
neurodegenerative diseases.  
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  AIMS OF THE STUDY	  
	  
The purpose of this study was to understand the organization and involvement of the 
dopaminergic system in the zebrafish model of PD and use this species to study the 
mechanism underlying the genetic forms of PD caused by pink1 dysfunction. 
In particular, the study had the following goals:  
1. Identification and expression analysis of the two different isoforms of tyrosine hydroxylase 
(TH) genes in zebrafish and their involvement in different PD models. 
2. Characterization of the effects of pink1 knockdown on larval zebrafish behavior and neural 
systems. 
3. Identification of specific genes and pathways affected by pink1 dysfunction using 
microarrays. 
4. Detailed functional analysis of the genes and the pathways identified by the microarray 
analysis following pink1 knockdown. 
5. Creation of a pink1 transgenic fish model and use of this to study the effects of oxidative 
stress in larval zebrafish. 
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MATERIALS AND METHODS 
1. Experimental animals 
Larval and adult zebrafish from the Turku line were used. The Turku line was originally 
obtained from a pet source and maintained in the laboratory for over a decade. It has been 
used in previously published studies [12, 142, 177]. Zebrafish were bred in groups and 
embryos were collected and staged as described by Kimmel et al. [178]. The permits for the 
experiments were obtained from the Office of the Regional Government of Southern Finland 
in agreement with the ethical guidelines of the European Convention. 
2. Morpholino oligonucleotides (MOs) knockdown technique and RNA rescue 
To knockdown the pink1 gene, two MOs (Gene Tools) were used. One targeted the splice site 
at the exon 3 and intron 3 boundary (MO1, TCACAACCTACCCGTTCAAAGTCAG) and 
the other targeted the 5′-UTR site (MO2, GAGAGGAAATCTGAAGGCTTTTACG). A 
standard control MO with no observed adverse effects (ctrlMO, 5′-
CCTCTTACCTCAGTTACAATTTATA 3′) was used in all quantitative RT-PCR 
experiments. Other controls included the injection of water in place of MO as an injection 
procedure control and normal uninjected fish. A 4-nl volume of MO solution (25% phenyl 
red + MO in sterile water) was injected into the yolk at the 1–2-cell stage. Amounts of 8 ng 
MO1 and 4 ng of MO2 were used. The embryos that were injected with MO at the one-cell 
stage were screened for fluorescence a few hours post-injection. The embryos that showed 
fluorescence were selected and raised in petri dishes for further experimentation. 
 
The pink1 full-length cDNA was prepared by RT-PCR. Total RNA was isolated from adult 
zebrafish brains using the RNAeasy mini kit (Qiagen). The first-strand cDNA was 
synthesized using 3 µg of total RNA and Superscript III reverse transcriptase (Invitrogen). 
The cDNA was then amplified with a Phusion High-Fidelity PCR Master mix (Finnzymes) 
using the forward primer (5′-TTGAATTCTCTATTTGGCTC-3′) and the reverse primer (5′-
ACATTAGATCTAGACTCTCTTGGC-3′). The resulting PCR product was cloned into the 
pGEM-T Easy vector (Promega) and sequenced. The clone with no mutations was digested 
with EcoRI and the insert was cloned into the pMC expression vector [179]. Capped sense 
transcripts from the cDNA expression clone were generated by using the mMESSAGE 
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mMACHINE kit (Ambion). For the RNA rescue experiment, 500 pg of pink1 mRNA with 
4 ng of MO2 or 8 ng of MO1 was coinjected into embryos at the one-cell stage. 
3. In situ hybridization  
The embryos were depigmented in 0.003% phenylthiourea (PTU) in E3 medium at 24 hpf. At 
2 dpf, fish were fixed in 4% PFA in phosphate buffered saline (PBS) o/n at +4 °C.  The 
fixative was changed the next day to 100% methanol and the samples were stored at -20 °C 
until further use [180]. 
For in situ hybridization, embryos were rehydrated in a 70%, 50%, 25% methanol series and 
washed twice with PBS with 0.1% Tween 20 (PBST). The specimens were treated with 
10 µg/ml of proteinase K for 10 minutes and again treated with the same fixative for 20 min. 
After washing several times with PBST, the embryos were pre-hybridized in hybridization 
buffer (HB, 50% formamide, 5x SSC, 5 mg/ml yeast tRNA, 100 µg/ml heparin and 0.1% 
Tween 20 in DEPC water) at 70 °C for 2 hours followed by hybridization overnight with the 
riboprobe in the hybridization chamber. The specimens were washed the next day with 75% 
HB, 50% HB, 25% HB in 2 x SSC series following one wash with 2 x SSC and 2 times 0.2 x 
SSC for 30 minutes. For probe detection, the embryos were pre-incubated with a blocking 
buffer (PBST, 1% BSA and 1% sheep serum) for 2 hours at room temperature and then 
rocked overnight with 1:5000 anti-DIG antibody conjugated with alkaline phosphatase 
(Roche) in the blocking buffer at +4 °C. After several washes with PBST, hybridized probe 
was detected with a colorimetric detection method with 450 µg/ml NBT (nitro blue 
tetrazolium chloride) and 175 µg/ml BCIP (5-bromo-4-chloro-3-indolyl phosphate, toluidine 
salt) (Roche). The color reaction was stopped by several washes in PBST followed by 
infiltration with 30%, 50% and 70% glycerol. The samples were mounted in 90% glycerol 
and imaged with a Leica inverted microscope. 
Probes for th1, th2, pax2a, dat, notch1a, and vegfs (vegfaa, vegfab and vegfc) were 
synthesized from different plasmids with specific restriction enzymes and polymerases, as 
described in detail in the publications. The digoxigenin (DIG)-labeled probes were generated 
with the DIG RNA labeling kit according to the manufacturer’s instructions (Roche). 
Bright-field images were taken using a Leica DM IRB inverted microscope with a DFC 480 
charge-coupled device camera using the multi-focus option, and z-stacks were processed with 
Leica Application Suite software and CorelDRAW 12 software (Synex). 
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4. Immunohistochemistry 
Embryos of different ages were fixed with 4% PFA overnight at +4 °C. The samples were 
washed 3 x 30 min with PBST at RT followed by pre-incubation with PBST, 1% DMSO, and 
4% normal goat serum (NGS) for 4 hours at RT. Anti-GFP, chicken IgY fraction 
(Invitrogen), was used for staining the transgenic lines at 1:800 dilution o/n in PBST with 2% 
NGS at +4 °C. The samples were washed 3 x 30 min in PBST followed by incubation with 
goat anti-chicken antibody at 1:1000 dilution o/n at +4 °C. The samples were then washed 
again 3 x 30 min in PBS followed by 2 x 60 min infiltration with 50% glycerol in PBS. 
Immunofluorescence samples were mounted in 80% glycerol and examined using a Leica 
TCS SP2 AOBS confocal microscope. For excitation, an argon laser (488 nm) was used. 
Emission was detected at 500–550 nm, as described earlier [12,17]. Stacks of images taken at 
1.2-µm intervals were compiled, and the maximum intensity projection algorithm was used to 
produce final images with Leica Confocal Software. Pictures were then compiled in Corel 
Draw 12 software. 
Rabbit anti-PINK1 (Cayman Chemicals, 1:1000), mouse anti-TH (1:1000), 5-HT (1:1000) 
and mouse anti-ZRF-1 ([181]1:500) antibodies were used. These antibodies have been 
applied in previous studies[12,142]. Anti-GFP, chicken IgY fraction (Invitrogen), was used 
for staining the transgenic lines at 1:500 dilution. To visualize lateral line neuromasts, 5-dpf 
larvae were incubated in 25 nM Mitotracker Red (Invitrogen) for 15 min at RT, rinsed, fixed 
in 4% PFA, and incubated with anti-acetylated tubulin antiserum (Sigma) diluted 1:1000. 
5. Microarray and data analysis 
RNA was isolated from wildtype and pink1 MO1 using the RNAeasy minikit (Qiagen). The 
quality of RNA was determined with a bioanalyzer and the RNA integration number (RIN) 
was determined. A RIN above 8 was considered for further processing. Hybridization of 
samples was performed on Agilent 4 x 44k microarrays, (Agilent Technologies) at the 
Biomedicum Biochip Centre, Helsinki, Finland according to the manufacturer’s 
recommendations. Agilent offers two versions specifically for zebrafish, and we used the 
two-color chip V1 array version specifically for zebrafish in this study. The V1, referred to as 
the first version, is the one whose contents are sourced from RefSeq, UniGene, TIGR, and 
UCSC Zebrafish. 
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Analyses were carried out with R 2.7.0 and Bioconductor 2.2 packages Limma, Category and 
GOstats (http://www.bioconductor.org/). First, data were background corrected using the 
normexp method [182] with an offset of 50, which ensures that all expression value estimates 
are positive. Before statistical analyses, replicate spots were averaged. Chemical dyes differ 
in their fluorescence at different excitation levels due to differences in their quenching 
properties. For a normalization method that can remove such intensity-dependent effects in 
the log2 (ratio) values of the green and red dye used in the array, we carried out normalization 
using the loess method (locally weighted linear regression curve), as it removes dye 
unfairness in the two-color array experiment [183]. To find the differentially expressed 
genes, an empirical Bayes method was used. The Benjamini and Hochberg false discovery 
rate (FDR) was used to correct the p-values for multiple comparisons [184]. Genes with an 
FDR value of less than 0.05 were considered as differentially expressed. Hypergeometric 
tests were used in assessing whether differentially expressed genes were enriched into any 
KEGG pathways or GO ontology classes [185]. Genes in pathways or classes with a p-value 
less than 0.05 were considered significantly over-represented. 
 
The raw normalized data set was used in the Ingenuity Pathways Analysis program 
(Ingenuity® Systems, version 8.7, http://www.ingenuity.com/) to identify significant 
pathways. Canonical pathway analysis in IPA was used to identify specific genes that are 
functionally significant and are present within the networks. Genes differentially expressed 
with a p-value < 0.01 were overlapped in the available networks developed from information 
contained in the ingenuity pathway knowledge base. In the current study, a score of 10 or 
higher was used to select highly significant biological networks. 
6. RNA isolation and quantitative RT-PCR 
All independent RNA samples were isolated from pooled embryos (30 embryos/sample) 
using the RNAeasy Mini Kit (Qiagen) as described above. RNA was reverse transcribed to 
produce cDNA from the samples using superscript reverse transcriptase-II and also 
superscript reverse transcriptase-III (Invitrogen) primed with oligo (dT) primers according to 
the manufacturer’s instructions for different experiments. The same superscript reverse 
transcriptase was used throughout for each individual experiment for comparability. 
SmartCycler instrumentation (Cepheid) was used to amplify the specific gene transcripts. The 
Q-RT-PCR analysis was performed with the SYBR green mix (Takara) as per the 
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manufacturer’s instructions in smart cycler tubes in a total volume of 25 µl. The composition 
of the reaction mixture was the following: SYBR green mix 12.5 µl, diluted cDNA 1–3 µl, 
primers at a final concentration of 1 µM. Primers for amplification were designed using 
Primer Express software v3.0 (Applied Biosystems). 
7. Microscopy and image analysis 
Light microscopic analysis was performed using a Leica DM IRB inverted microscope (Leica 
Microsystems) connected through a Leica DFC 490 Color Digital Camera to Leica 
Application Suite 2.7.0 R1 software. Fluorescence microscopy was carried out using a Leica 
TCS SP2 confocal microscopy system with an argon laser having a 488-nm laser line, a green 
diode laser with a 561-nm laser line, and a HeliumNeon laser with a 633-nm laser line. All 
double- or triple-stained samples were scanned sequentially to reduce crosstalk between 
channels. Images were obtained in 1024 x 1024 pixel format. Stacks of images were taken at 
0.2-µm intervals. The maximum intensity projection was compiled from these using Leica 
confocal software. Figures were compiled with CorelDraw 12 software (Corel Corporation, 
Ottawa, Canada). Three-dimensional modeling was carried out using Imaris 6.0 software 
(Bitplane).  
8. Reactive oxygen species (ROS) detection and heart rate measurement 
The accumulation of ROS inside cells was detected with 2′,7′-dichlorofluorescin diacetate 
(H2DCFDA) (Sigma-Aldrich). This is a common fluorogenic dye and oxidant-sensitive probe 
that is oxidized by ROS to produce green fluorescent dichlorofluorescein[186]. It was used at 
a concentration of 5 nM for 30 min at 28 °C. At 1 dpf, 2 dpf, 3 dpf, and 5 dpf, ten individuals 
per group were taken and each set of experiments was repeated at least in triplicate. 
Fluorescence was observed using a Leica confocal microscope under 488-nm wavelength 
excitation after mounting the fish in 2% methylcellulose. For excitation, an argon laser (488 
nm) was used. Emission was detected at 500–550 nm. 
 
The heart rate was obtained from zebrafish larvae at 2 dpf and 6 dpf. It was measured by 
determining the number of beats per minute for each fish in the group (n = 25) under a 
stereomicroscope, repeated independently three times. The average value obtained from 
triplicate measurements was recorded as the number of beats per minute for each individual 
fish. 
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9. O-dianisidine staining 
Hemoglobin (Hb) activity was detected in whole embryos using the o-dianisidine staining 
method [187]. Embryos at 1, 3 and 5 dpf were fixed with 4% PFA o/n and washed 3 x 30 min 
in PBS. They were then placed in freshly prepared o-dianisidine stain solution (40% ethanol 
with 0.01 M sodium acetate, 0.65% H2O2, and 0.6 mg/ml o-dianisidine [D-9143; Sigma, St. 
Louis, USA]) for 30 min in the dark with regular monitoring of the color development and 
then washed several times in PBS. The basis of this assay is that Hb catalyzes the H2O2-
mediated oxidation of o-dianisidine, producing a dark red color in Hb-positive cells. The 
embryos were stored in 80% glycerol until they were imaged using a Leica inverted light 
microscope. Bright-field images were taken using a Leica DM IRB inverted microscope with 
a DFC 480 charge-coupled device camera, and z-stacks were processed with Leica 
Application Suite and Corel Draw 12 software. Dark red colored Hb-positive cells were 
counted only in the brain region of the embryos for quantitative purposes. 
10. Catalase assay  
Catalase activity was assayed by using the CAT 100 kit (Sigma-Aldrich, St. Louis, MO, 
USA). Larvae at 2 dpf were fresh frozen in liquid nitrogen and homogenized using RIPA 
buffer (Tris-HCl 50 mM, pH 7.4, 1% NP-40 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM 
EDTA, 1 mM NaF) with one mini-complete protease inhibitor tablet (Roche) added in 10 ml 
of solution just prior to use. The homogenized sample was centrifuged at 16000 x g in a 
Spectrafuge 16M Microcentrifuge (Labnet systems, NJ, USA) for 30 min at +4 °C. The 
supernatant was collected and protein was measured using the BCA assay (Thermo Fisher 
Scientific, IL, USA). An equal amount of protein for each sample was taken while preparing 
the samples. H2O2 standards and the samples were made according to the manufacturer’s 
instructions and OD was measured at 540 nM with a Multiskan MS Plate Reader 
(Labsystems, Midland, Canada). The catalase activity was calculated as:  
Activity   =   Δ x D x 100 
                           V x t 
where,               
Δ = difference in the amount of H2O2 added to the colorimetric reaction between the blank 
and a given sample 
D = dilution factor 
t = catalase reaction duration 
V = sample volume in the reaction 
100 = dilution of aliquot from the catalase reaction in the colorimetric reaction 
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11. Behavioral analysis 
The fluorescence-sorted embryos were dechorionated at 24 hpf and transferred to 6-well 
plates. Each well contained 30 embryos. Larval fish were then raised in the wells of 6-well 
plate containing 3 ml of E3 medium. MPTP (Sigma, St. Louis, MO) was added to the E3 
medium at a final concentration of 50 µM at days 1–4 and replaced daily. Fish were tracked 
at 5 dpf and 6 dpf using a CCD camera connected to a computer and analyzed using 
Ethovision 3.1 software (Noldus Information Technologies). 
 
The fish were placed in a 48-well plate with one fish and 1 ml of E3 in each well. The arenas 
were calibrated in advance, before placing the plate with the fish under the camera. They 
were analyzed for 10 mins at a sample rate of 5 frames per second. The total distance moved 
(cm), turn angle (degrees) and movement (percentage of time fish spent moving) were 
calculated from the coordinates acquired using EthoVision software. Before tracking, system 
noise was removed using an input filter of 0.2 cm for the minimum distance moved. Tracks 
were excluded where the sample size was less than 90% of the maximum sample size or if 
large reflections were detected [188]. All experiments were performed at room temperature 
and were replicated at least three times. 
12. Tol2 mediated transgenesis 
The region of interest with minimal promoter activity was designed at -2 kb upstream of the 
transcription start site of pink1. This was based on Tol2-mediated transgenic technology 
[148]. The primers used for amplifying the gene promoter were as follows: 
GGGGACAAGTTTGTACAAAAAAGCAGGCTAATGATGCATCTCAGTCATTC as the 
forward primer and 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTTTACTGACATTTTGAGCCAA as the 
reverse primer. The gateway cloning kit (Invitrogen) was used in this process due to its 
cloning efficacy for large inserts. The primers were designed to add attB sites to the final 
product to be inserted into the donor vector pDONR221 to perform the first reaction step of 
the gateway cloning kit. The clone was PCR verified and the insert was transferred into the 
destination vector pXIG-cfos-GW [163]. 
 
The transposase cDNA, used for injection, has been cloned in the pCS-TP vector. The mRNA 
was synthesized in vitro using the mMESSAGE mMACHINE SP6 Kit (Ambion Inc.). This 
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mRNA has an SV40 polyA tail in the 3’ region. Next, 25 ng/µl of circular DNA with the 
gene of interest and 25 ng/µl of transposase mRNA were injected into the one-cell stage of 
fertilized eggs. 
 
We outcrossed founder fish (F0) with wild-type fish and collected the progeny embryos (F1) 
with GFP under a fluorescence microscope. The GFP expression was visualized in the 
injected embryos, and three different founder lines differing in the levels of GFP expression 
were identified. Out of these founders, only one line was chosen and named Tg(pink1:EGFP) 
based on the maximum GFP expression pattern, which was crossed and grown up as the 
stable line of embryos (F2). These fish were grown until adults and experiments were 
performed on all the fish from the F2 generation onwards.  
13. Chemicals 
Hydrogen peroxide (H2O2) (Merck, NJ, USA) was used at a concentration of 5 µM in E3 
medium for 20 mins to create an oxidative stress environment for the studies on wild-type 
and transgenic fish. L-Glutathione Reduced (LGR) (G4251) and N-acetyl cysteine (NAC) 
(A7250) (Sigma-Aldrich, St. Louis, MO, USA) were used at a concentration of 100 µM for 
24 hours as the antioxidant treatment after H2O2 treatment [189]. The same dose was also 
used in the pink1 (MO1) morphant study.  
14. Statistical analysis 
Statistical analyses for Q-RT-PCR, heart rate determination, red blood cell counts, behavioral 
analysis, and catalase assays were carried out using GraphPad Prism 4.01 software 
(GraphPad Software). The unpaired t-test was used for single comparisons, and one-way 
analysis of variance (ANOVA) followed by the Bonferroni post hoc test was applied for 
multiple comparisons. 
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RESULTS 
1. Gene duplication for tyrosine hydroxylase in the zebrafish: th1 and th2 (I) 
The gene encoding tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine 
synthesis, is highly conserved among different species and has been duplicated during 
vertebrate evolution. In mammals there is only one TH, while in teleost fish, two non-allelic 
genes have been found for TH [14]. We were the first to find two th genes in the zebrafish 
genome, orthologous to other teleosts: one located on chromosome 25 and the other on 
chromosome 4. It was, however, unclear whether the gene duplication occurred within the 
teleost lineage or as a result of whole genome duplication in ancestral vertebrates. A recent 
study revealed that duplication of the th genes is not only found in teleosts, but also in other 
non-eutherian vertebrates [190]. 
 
Expression levels of the th genes are differentially regulated during development, and 
expression was detected in multiple brain nuclei. The transcript levels of both the genes 
remain unchanged during the first 12 hpf, but th1 expression levels gradually increased above 
those of th2 from 5 dpf. The highest expression of th2 was found in the kidney and liver. The 
transcript expression of th2 in the adult tissues indicated a more peripheral function than in 
the brain. All previous studies using TH antibodies have only detected th1 expression and not 
th2, as has been found in colocalization studies [13]. Based on their immunoreactivity, TH 
populations have been numbered in an anterior to posterior direction in the brain of the 
zebrafish to help in identification and labeling. The groups and numbering are as follows: 
olfactory bulb and telencephalon (1, 2), pre-optic region (3, 4), diencephalon (5, 6, 11), 
pretectum (7), anterior paraventricular organ (8), intermediate paraventricular organ (9), 
posterior paraventricular organ (10), posterior tuberculum (12), caudal hypothalamus (13), 
locus coeruleus (14), internal reticular formation (15), caudal lobe (16) and commissural 
nucleus of cajal (17) [17]. Expression of th2 mRNA was detected by ISH and the cell groups 
have been numbered as the anterior (8b), intermediate (9b), and posterior parts of the 
paraventricular organ (10b) and the preoptic region (3b) (Figure 3b). This numbering of th2 
cell groups was adopted in coherence with the th1 cell clusters. Some other research groups 
have used a different nomenclature for both the th1 and th2 in the zebrafish [190, 191]. The 
location of th2 cell groups has been verified by combining in situ hybridization for both of 
the transcripts. Immunohistochemistry for the TH antibody has also been performed in 
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combination with th2 in situ [13]. The differences that we detected for both forms of TH in 
expression, timing, pattern, and distribution are in agreement with the concept that TH genes 
are differentially regulated at the transcriptional and translational levels [14]. The 
conservation of the dopaminergic system between the mammalian system and the zebrafish 
has been illustrated below (Figure 3).  
 
Despite the enormous variation in brain morphology and complexity among the vertebrate 
species, there are six main groups of catecholaminergic cells, out of which groups A9–A16 
represent the DA cluster [192]. In zebrafish, the catecholaminergic populations are 
represented by a combination of groups of th1 and th2. Groups 1–17 represent the th1 group, 
and the complementary expression of th2 is represented by 3b, 8b, 9b and 10b.  
 
Figure 3. Localization and comparison of discrete dopaminergic cell groups in the sagittal 
view of (a) the mouse and (b) the zebrafish brain. (a) A9–A16 DA clusters of the mouse brain 
(modified from[90](b) Representative th1 and th2 cell groups in the zebrafish brain, color 
coded according to the expression pattern from dorsal to ventral [13]. 
2. Zebrafish Pink1 gene structure and expression (II and IV) 
The pink1 gene is involved in the early onset form of PD, but its comprehensive function is 
still not yet understood. There are two specialized regions in the gene essential for PINK1 to 
function properly. These functional domains are highly conserved across species. The pink1 
gene is located on chromosome 23 in the zebrafish genome. It is comprised of eight exons 
and encodes a 574-amino-acid protein with a predicted mass of 64 kDa. PINK1 shares 
58.45% nucleotide and 56.61% amino acid similarity with humans. The mouse knockout 
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model did not show a critical phenotype, as in the human disease counterpart, which is why 
there came a greater need for other model organisms. 
 
PINK1 expression has been found to be ubiquitous, but differences in the expression levels 
nevertheless exist in all tissues. By semi-quantitative RT-PCR, the expression of pink1 
mRNA could be detected from as early as 3 hpf until adulthood. With a thorough analysis by 
real-time PCR, we found that the expression increases significantly more at 5 dpf onwards. 
At the tissue level, the transcript was found to exist in all organs. In the brain, the highest 
levels were recorded in the forebrain and midbrain. In situ results revealed pink1 gene 
expression in the brain, eyes, heart, liver, muscle and lateral line. 
 
The PINK1-ir results demonstrated widespread expression in the brain gray matter. It was 
detected in comparable regions to the mRNA distribution. In the morphant discussed in detail 
below, PINK1-ir was abolished. It could be rescued by pink1 mRNA injection, proving that 
the polyclonal antibody was able to detect PINK1. As an additional means to examine pink1 
expression, we created a transgenic reporter line -2 kb upstream of the transcription start site 
of the gene by using the tol2 transposition method. This line revealed a more specific 
promoter-driven expression pattern of PINK1. The prominent GFP expression showed the 
highest levels in the telencephalon, midbrain and rhombencephalon, continuing to the spinal 
cord. GFP-ir was also found in the heart, liver and muscle at 5 dpf. The transgene expression 
colocalized with the PINK1 antibody. 
3. Characterization of Pink1 knockdown fish (II) 
To study gene function in the zebrafish, a sequence-specific knockdown of gene expression is 
mediated by morpholino oligonucleotides (MOs). While this study was being carried out, 
another paper was published on the zebrafish model in which pink1 was knocked down. The 
fish showed greater variability and a severe phenotype, a series of observations surrounding 
unanticipated effects that were independent of the intended gene target. Gene knockdown by 
MOs is known to trigger off-targeting effects by p53 activation [143]. We therefore made two 
different MOs to check for the specificity and authenticity of the gene knockdown. By 
validating the data with controls for tp53 and Δ113 transcripts, we established that pink1 
knockdown did not show highly deleterious phenotypic effects such as those previously 
reported [16]. One of our translational blocking MOs (MO2) showed a dismorphic external 
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phenotype that could be partially rescued by pink1 mRNA injection. However, the splice 
blocking MO (MO1) did not show any obvious external phenotype, as has been observed in 
mice knockout models and also in human disease counterparts. The fish were 
indistinguishable from the wildtype counterparts in their external morphology. Therefore, we 
proceeded with MO1, the efficacy of which could be quantified by RT-PCR [193] (Figure 
4a). The tp53 and Δ113 transcripts were highly upregulated in MO2- but not in MO1-injected 
fish (Figure 4b and 4c). Therefore, only MO1 was used for all further experimentation. 
 
Figure 4. Validating the efficiency of pink1 knockdown by MO. (a) Effective knockdown by 
MO1 as detected by RT-PCR. (b) Comparison of MO1 and MO2 by checking the tp53 
transcript by Q-RT-PCR. Pink1 mRNA could not rescue the tp53 effect. Injecting p53 MO 
reduced the transcript, but not up to the control group level. (c) Only the MO2 group showed 
extensive up-regulation of the Δ113 transcript by Q-RT-PCR. All statistical comparisons with 
the control uninjected (UI) group were performed by one-way ANOVA with the Bonferroni 
post hoc test (* p < 0.05 ** p < 0.01, ***p < 0.001). 
 
In pink1 morphants, we observed a clear reduction in th1and th2 transcripts in the absence of 
any striking external phenotype. This was also evident in the in situ results, and both of the 
phenotypes could be rescued by pink1 mRNA co-injection (Figure 5). The TH-ir, which 
mostly detects th1, showed that there was a reduction in cell groups of the pre-tectum (group 
7) and in the diencephalic region (5,6,11) of the morphant as compared to the control. The 
th1 transcript also revealed a decline in the reaction in the ventral diencephalic cluster (Figure 
5 A–C). For th2, no antibody is currently available that could determine the protein 
expression pattern of all the groups. Therefore, we used only in situ hybridization to locate 
the decline in the th2 transcript in the pink1 morphant. The decline was observed in groups 
8b, 9b and the large 10b group in the hypothalamus. All the loss of th2 expression was 
rescued by pink1 mRNA (Figure D–F). 
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While the dopaminergic populations were exacerbated, we also analyzed possible changes in 
the other neurotransmitter systems. No significant change in hdc and dat transcripts was 
detected in the morphants. There was also no change in the immunoreactivity patterns for 
orexin, calretinin, ZRF-1, or NPFF (Neuropeptide FF). Histamine IHC could not be 
performed because the ir is better detected at 7 dpf, and by that time the MO effect becomes 
diluted. In summary, knockdown of pink1 leads to specific effects in the dopaminergic 
neurons, while other neuronal subtypes remain unaffected. 
 
Figure 5: In situ hybridization with probes for th1 and th2 in pink1 morphants at 3 dpf. A–C: 
The decline in the th1 transcript was recovered by pink1 mRNA injection. D–F: The th2 
transcript could also be rescued by pink1 mRNA. 
4. Effects of Pink1 knockdown on MPTP toxicity (II) 
A combination of environmental and genetic factors influences the etiology of PD, and we 
therefore examined whether pink1 morphants are sensitized to MPTP. Loss of pink1 
generated significant sensitivity to damage induced by systemic MPTP treatment. The MPTP 
concentration to treat the morphants was selected after a careful dose-dependency analysis. 
MPTP was administered to the morphants at 50 µM from 1 dpf until 5 dpf. At this 
concentration there were no detectable alterations in the gross morphology, spontaneous 
locomotor activity, or TH-ir in the brain of normal zebrafish. Therefore, this was regarded as 
a sub-effective dose. After exposure of the pink1 MO1 at 5 dpf to this concentration of 
MPTP, there was a significant decline in the TH-ir cell neurons in the pretectal population, 
but no significant decline in the cell group 5, 6, 11. For the other MO2, the decline in TH 
populations in the pre-tectal population and 5, 6, 11 were significant. Thus, TH-ir was 
sensitized by further addition of MPTP in pink1 morphants. 
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5. Effects of MPTP along with Pink1 knockdown on fish behavior (II) 
We examined the collective effect of pink1 knockdown and MPTP treatment on larval 
motility. The pink1 MO1-injected fish were subjected to MPTP from 1 dpf until 4 dpf. After 
one day of recovery, the swimming pattern was tracked and the total distance moved was 
calculated for each group. No changes were observed for MO1-injected fish, fish treated with 
MPTP alone, or the control group. Following MO1 injection and exposure to MPTP, the 
swimming pattern was disturbed and the total distance moved was considerably reduced. 
There was no alteration in the other parameters such as the turn angle, meander, or angular 
velocity measured during the behavior acquisition. This led us to conclude that a lack of 
pink1 makes the fish highly vulnerable to sub-effective concentrations of MPTP that affect 
the locomotor activity, which was observed in the altered swimming pattern.  
6. Pink1 function analysis and novel pathways (III) 
A microarray study was carried out using the pink1 morphants to identify the roles of key 
genes and pathways affected by the loss of pink1 function. This resulted in identifying 177 
genes that were significantly altered in pink1 morphants compared to wild-type fish at a cut-
off p-value < 0.05 using the program R version 2.7.0. The microarray data were filtered quite 
stringently for the fold-change and p-value, which are the most critical factors for successful 
data analysis. We validated the array results with qPCR on many independent samples and 
compared the fold change values between the two methods. The altered genes showed similar 
trends with both methods. Each gene expression alteration could also be rescued by pink1 
mRNA injection. This demonstrates the efficiency of the microarray results. 
 
To find potential pathways affected by pink1 knockdown, we used the commercially 
available Ingenuity pathway analysis program. This helped us identify a novel pathway that 
was affected by pink1 dysfunction. The HIF signaling pathway was carefully scrutinized by 
using different independent assays and methods to determine whether only the transcription 
factor hif1a was affected or other targets of the same pathway were also altered. We have 
previously found that TH transcripts decline in pink1 morphants. Experimental evidence from 
primary neuronal precursor cells suggested that HIF1 inactivation in the substantia nigra 
leads to a 41% reduction in the TH marker in the dopaminergic neurons [125]. While there 
was a decline in antioxidants such as cat and sod2, increases in erythropoiesis, ROS, notch1a, 
and VEGFs (vegfaa, vegfab and vegfb) were also observed. In the zebrafish genome, there are 
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still many gaps in the annotation that need to be curated. Following regressive curation, we 
could also be able to potentially map all other transcripts that were altered. The effect of 
pink1 knockdown on erythropoiesis and both TH transcripts could be rescued by the addition 
of antioxidants such as LGR and NAC. This was, to our knowledge, the first time that the 
phenomenon had been reported, and provided an important link to identify HIF signaling in 
the context of pink1 dysfunction. The HIF signaling pathway may now prove useful for drug 
development towards the prevention or cure of Parkinson’s disease. This suggests pathway-
specific therapies may need to be developed for PD patients with diverse molecular 
etiologies. 
7. Pink1 and neuroprotection (IV) 
Many studies have suggested that PINK1 can protect neurons from apoptosis induced by 
oxidative stress and neurotoxins [194, 195]. To carefully monitor the in vivo expression of 
pink1, we generated a transgenic fish line using the Tol2 transposon, which expressed GFP 
under the pink1 promoter. This line was named Tg(pink1:EGFP) and was used to study the 
effect of oxidative stress on pink1 expression. The expression pattern of the pink1 GFP was 
similar to the in situ pattern in the zebrafish larvae. A very low concentration of H2O2 was 
chosen to mimic oxidative stress as in the environment in vivo. This concentration did not 
affect the survival rates or normal external phenotype of the larval fish. Addition of H2O2 
increased the transgene GFP levels, which were detected in the brain of larval fish by GFP-ir. 
No change was observed in TH-ir in the same fish by double immunostaining. Another set 
from the same batch of fish was treated with the antioxidant LGR to observe whether any 
change occurred in the transgene levels. The increased transgene effect was rescued by the 
addition of the antioxidant LGR. The transgene expression level was almost comparable to 
the untreated samples. This experimental evidence suggests that pink1 is highly receptive to 
oxidative stress-mediated challenges, and this can be easily visualized in vivo by using this 
model. 
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DISCUSSION 
Model organisms provide an important platform for the analysis of human disease processes 
and the development of therapies. The use of model organisms for the analysis of disease 
relies on the underlying conservation of pathways and processes between the organism and 
humans. Through the development of gene targeting via homologous recombination, the 
knockout mouse has become a paradigm of disease modeling. Many studies have highlighted 
the difficulty of recapitulating the pathology of human diseases in mice, for 
example[168,196]. Drosophila and C. elegans, being invertebrates, also have major 
drawbacks for this purpose. This problem has prompted the use of multiple model organisms 
to study disease in an effort to highlight conserved vs. organism-specific processes.  
 
Understanding of the neurobiology behind the monogenic variant, Pink1, as a cause of PD 
was the main objective of this study. We reasoned that the zebrafish offers an economical and 
rapid alternative for testing and designing novel therapies for PD. Although they do not 
substitute the other mammalian models, zebrafish offer complementary benefits such as 
convenient genetic manipulation to assess the role of different genes and their regulation for 
better understanding of the disease. The work described here supports the use of zebrafish as 
a critical vertebrate species for the modeling of human PD mediated by Pink1. 
1. Zebrafish genome and gene structure 
Analysis of the zebrafish genome suggests that the zebrafish and human lineages have shared 
two rounds of whole genome duplication, and a third whole genome duplication occurred just 
prior to the teleost radiation. Therefore, for many genes in humans, there maybe two copies 
in zebrafish [197]. Analysis of a group of genes that is syntenic in humans tends to have 
orthologs that are syntenic in zebrafish. The evolutionarily distant human and zebrafish 
genomes share the shortest synteny blocks, which correspond to ancient essential cis-
regulatory regions. The developmental genes in humans represent the largest blocks of 
synteny, and these are conserved all the way to teleosts. This establishes that these conserved 
blocks of synteny in the genomes of vertebrates are kept intact as a general principle of 
development and gene regulation [198]. The study of regulatory elements is possible with the 
help of enhancer screening and transgenic technology [130]. These regulatory elements of a 
gene, which are not regulated by the gene itself but by a target further away from the gene, 
can be studied by taking the conserved synteny into account.  
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Taking into consideration the conserved syntenies between zebrafish and mammals, 
candidate genes can be selected for disruption and studied by a myriad of genetic 
manipulations in zebrafish. Reciprocally, if the phenotype of a zebrafish mutation can 
suggest functions for a human gene, this can also be studied with cellular precision. This may 
provide an efficient way of assigning functions to essential orthologous human genes, which 
are only known by their sequence from the human genome project. In this way, the molecular 
and formal genetics of the zebrafish can contribute to functional human genomics. 
2. Molecular and genetic characterization of zebrafish Pink1 
2.1. Distribution of Pink1 in the larval and adult brain of zebrafish 
The distribution of the gene in larval fish was studied by in situ hybridization with a pink1 
full-length probe. The regions of strong pink1 expression during development at 5 dpf 
included the developing heart, liver, lateral line, and brain. These are areas that are 
particularly energy consuming. The mitochondria, which are also referred to as the 
powerhouses of the cell, support the cell with the requisite amount of energy via the electron 
transport chain [199]. PINK1 was shown to localize in mitochondria, thus suggesting an 
essential role of PINK1 in mitochondrial function [200]. Other areas of strong pink1 
expression in the brain during embryonic development were found to be the telencephalon, 
thalamus, hypothalamus, midbrain, and rhombencephalon. Using PINK1-ir, we detected the 
expression of pink1 in almost all brain areas, but mostly in the gray matter. The white matter 
was devoid of any staining. This is consistent with the findings in rodents [201, 202]. In one 
study, PINK1 has been found in glial and endothelial cells [59], but the lack colocalization 
with the zebrafish zrf-1 antibody suggested that zebrafish PINK1 is absent in glial cells. In 
the larval brain, we detected mRNA as well as protein expression in the lateral line, which 
mainly functions in mechanosensation and the maintenance of sensory stimuli. Sensory 
abnormalities have been found in PINK1 heterozygote patients [45]. In summary, expression 
of pink1 in zebrafish closely resembles the expression reported in mammals. 
2.2. Pink1 knockdown and knockout models  
The main impact of Pink1 dysfunction in humans is Parkinson’s disease and the associated 
symptoms. Different model systems have been studied to recapitulate the disease progression 
in order to devise drugs that could cure PD or prevent disease progression. The common 
animal models that have been used to provide insights into the molecular pathology of 
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PINK1 mutations in PD include C. elegans, Drosophila, the mouse, and zebrafish. The 
findings have been summarized in a Table 2 below. 
Table 3. PINK1 knockout and knockdown in different animal models 
Model Animal Phenotypes References 
C. elegans 
Reduced mitochondrial cristae length 
Increased paraquat sensitivity 
Axon pathfinding defects 
Sämann et al. (2009) 
 
Drosophila 
Complete male sterility 
Downturned wing phenotype with rigidity and crushed thorax 
Severe locomotive defects (i.e., slower climbing speed and 
complete loss of fight ability) 
Reduced dopamine levels in brain tissues 
Specific loss of DA neurons in 30-day-old flies 
Increased sensitivity to paraquat and rotenone 
Mitochondrial swelling in sperm, indirect fight muscles, and DA 
neurons 
Decreased mitochondrial content and ATP levels in indirect flight 
muscles 
Clark et al. (2006); 
Park et al. (2006); 
Yang et al. (2006) 
Zebrafish 
Movement disorders (i.e., reduced swimming activity and impaired 
response to tactile stimuli) 
No significant alteration in the number of DA neurons 
Disorganized patterning of DA neurons 
Increased susceptibility to MPTP 
Sallinen et al. (2010) 
Xi et al. (2010) 
Medaka 
Decrease in dopamine metabolite 
Locomotory defects 
 
Matsui et al.(2010) 
Mouse 
No change in DA neuron numbers or dopamine levels in the 
striatum 
Decreased dopamine release under electrical stimulation 
Impaired mitochondrial respiration in the striatum 
Increased sensitivity to H2O2 and MPTP 
Left ventricular dysfunction 
Pathological cardiac hypertrophy 
Impaired olfaction, gait and serotonergic innervation 
Increased susceptibility to MPTP 
Age dependent decrease in the DA content in the striatum and 
reduced spontaneous voluntary activities 
Billia et al. (2011); 
Gautier et al. (2008); 
Kitada et al. (2007); 
Glasl et al. (2012); 
Haque et al. (2012) 
Gispert et al. (2009) 
 
The main goal of all the models is to recapitulate the key symptoms of the disease. All these 
animal models help us to obtain insights into the mechanisms underlying particular 
symptoms of PD, allowing us to investigate new therapeutic strategies and, in addition, 
provide an indispensable tool for basic research. As PD does not arise spontaneously in 
animals, characteristic and specific functional changes have to be induced by the 
administration of toxins or by genetic manipulation. The toxin models along with the genetic 
models are used because the etiology and progression of the disease can result from a 
combination of genetic factors and environmental exposures. 
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2.3. Pink1 knockdown and MPTP toxicity 
The discovery of MPTP essentially demonstrated that environmental agents could reproduce 
most, if not all, of the selective parkinsonian symptoms [64]. The relationship between 
neurotoxins and PD represents, in our view, an important step towards a better understanding 
of how genetic and environmental interactions may ultimately contribute to the pathogenesis 
of the disease. Thus, similarly to mammals, MPTP can produce significant dopaminergic 
neuronal loss in zebrafish [17]. Most toxins used in PD animal models inhibit mitochondrial 
function and reveal a greater susceptibility of dopamine neurons to mitochondrial dysfunction 
and ROS production. Many genes implicated in PD are directly or indirectly involved in 
mitochondrial function: PINK1, DJ-1, and possibly Parkin and LRRK2 are at least partly 
localized in mitochondria [3, 48]. 
 
In our study, a lack of pink1 increased the susceptibility of zebrafish to sub-effective doses of 
MPTP that affected the ventral diencephalic cluster of TH-ir. Therefore, it could be stated 
that the neurons in the ventral diencephalon of zebrafish are comparable to the mammalian 
nigrostriatal pathway [12, 15, 203]. This was the most vulnerable group to MPTP exposure as 
well as pink1 knockdown. While our study was being published, another report of MPTP in 
the pink1 -/- mouse model was identified. The pink1 -/- and knockdown mice were 
susceptible to MPTP and the effect could be rescued by the downstream genes parkin and dj-
1[204]. This result showed that pink1 -/- mice were more susceptible to MPTP, and this was 
not due to developmental compensation, because the transient knockdown of pink1 mice also 
produced similar results. The loss of pink1 together with exposure to MPTP has similar 
effects on DA populations in both the rodent model and zebrafish. These findings in two 
different models clearly demonstrate that endogenous pink1 is an essential component that 
prevents DA neuronal loss in response to environmental stress. The mechanism by which 
pink1 regulates survival has not yet been identified. The zebrafish toxin-induced models and 
mutants generated by advancements in knockout techniques such as TALEN, TILLING, and 
ZFNs could enhance current knowledge of disease progression in PD. Together, these studies 
might greatly facilitate the screening of small molecules or drugs for therapeutic purposes.   
3. Pink1, PD, and HIF-1 signaling  
Microarray technology has been successfully applied to the simultaneous expression of many 
genes and to large-scale gene discovery. These advancements and technological innovations 
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have resulted in massive mining of biological data[205]. The quality of gene expression data 
obtained from microarrays can vary greatly depending on the platform and procedures used. 
Variability in both technical and biological procedures can have a great impact on the 
analyzed results. Precautionary measures must be taken in the experimental design to 
minimize irregularities and ensure replicability. The quality of RNA is essential to obtain 
accurate results. The RNA integrity number (RIN) should always be checked for purity, and 
RNA with a RIN value below 8 should be discarded, because carry-over contaminants can 
affect the qPCR and also the array results. Quantitative RT-PCR is a commonly used 
validation tool for confirming the gene expression results obtained from microarray analysis. 
Both methods have many pitfalls, but for reliable data, rigorous normalization and robust 
experimental design would be useful. Our generated data were comparable using both of the 
methods, demonstrating the careful filtering, normalization, and a good experimental design. 
 
Current experimental and literature evidence has proved oxidative stress and impaired 
oxygen supply to be major players in the neurodegeneration process. This type of data has for 
the first time linked a genetic model of PD with HIF signaling. Such impartial high-
throughput analysis of pink1 knockout or knockdown has not yet been published. HIF-1 
activity is impaired by MPTP treatment in the PC12 cell line and also in mice[206,207]. 
Addition of the iron chelators clioquinol and desferrioxamine increases HIF-1α and protects 
against nigral degeneration by MPTP [207, 208]. Previous studies on neurotoxin-induced PD 
models have been used to test for HIF-1 association and iron chelators for neuroprotection. 
Many lines of evidence have demonstrated that HIF-1 is involved in the pathogenesis of AD, 
amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and a neurotoxin-based PD 
model [206]. Antioxidants such as LGR and NAC were found to be successful in providing 
neuroprotection in our pink1 knockdown study. The increase in HIF-1 activity following the 
addition of antioxidants such as LGR and NAC could combat oxidative stress, increase the 
blood oxygen supply, increase the synthesis of dopamine, and block cell death signaling 
pathways. This raises the possibility that HIF-1 is a potential therapeutic target for 
neurodegenerative diseases such as AD, ALS, HD, and PD. 
 
HIF-dependent gene expression can provide resistance to oxidative stress by regulating genes 
such as VEGF, erythropoietin, and MnSOD, which by themselves prevent oxidative stress-
induced cell death [209]. Many different PD models have been linked to the downstream 
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effector genes of HIF signaling. Abnormal regulation of VEGF has been linked to 
neurodegenerative disorders such as AD and PD [210]. These findings have come from both 
in vitro and in vivo toxin models. In the toxin-based PD rat model with rotenone and 6-
OHDA, VEGF-B is upregulated [211]. The neuroprotective effects of VEGFs should be 
considered as a potential disease modifying therapy for PD. Similarly, erythropoietin (EPO) 
neuroprotective effects have also been studied in the MPTP mice model [212]. While most of 
the genes were affected, some of the genes were also found to be unaffected by pink1 
knockdown. The hdc and dat transcripts remain unaltered throughout the morpholino activity, 
as detected by Q-RT-PCR [142]. 
 
All the previous PD models have interpreted their results based either on toxin models or 
genetic models, but not in combination. Our results for the first time link a genetic model of 
PD to the HIF signaling cascade. Before these new results can be fully interpreted, and before 
a specific hypothesis can be formulated to guide future experiments, it will be essential to 
obtain a more complete picture of the changes in gene expression under multiple 
experimental conditions. Microarray technology must be associated with functional studies in 
an effort to identify specific and selective biomarkers and druggable targets, thus allowing 
the successful discovery of disease-modifying therapeutic treatments. 
4.  The significance of the Pink1 transgenic model  
It is interesting that despite all the evidence for a role of oxidative stress in PD, relatively few 
studies have extensively characterized oxidative stress in animal models of PD. The 
transgenic models vary in the ease of manipulation and phylogenetic relatedness to humans, 
but they are still highly useful for research, especially into neurodegeneration [213]. Among 
the mouse models, the α-syn transgenic mouse is the best so far, because it can recapitulate 
the pathologies of synucleinopathy with protein aggregation and neurodegeneration [214]. 
Advances in mouse technologies provide unparalleled opportunities to refine or reinvent 
novel PD genetic mouse models, such as the Tet-off conditional transgenic approaches 
combined with the development of appropriate driver lines, and tamoxifen-sensitive Cre-
dependent gene deletion with temporal and regional control [215]. 
 
The ease of creating transgenic fish in the zebrafish model keeps it on par with other known 
vertebrate and even mammalian models. Experiments can be performed on zebrafish in a 
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noninvasive way at much higher spatial and temporal resolution. Utilizing the advantages of 
the fish system, we have characterized the Pink1 promoter region and identified a region 
upstream of the translation start site where minimal promoter activity was found when 
injected into the zebrafish embryos. The transgenic line was created using the Tol2 
transposon, a versatile and autonomously active transposon. Tol2 was identified in medaka 
fish, but has a greater transpositional activity in other vertebrates than medaka itself due to an 
extranuclear localization signal in the transposase protein [216]. This model could be used to 
study the endogenous function of pink1 in greater detail.  
 
The transgenic systems have immense importance for understanding the pathophysiological 
basis of disorders. These genetically modified animals have been instrumental in 
understanding the molecular disease mechanism and to screen for therapeutic compounds 
[213]. The TAU transgenic fish has been a valuable tool in studying potent GSK3β inhibitors 
[217]. The GAL4 driver lines are being generated to mirror the expression patterns of 
endogenous genes in order to target desired temporal and tissue-specific transgenic 
expression [218]. Thus, the development of PD genetic models holds tremendous potential 
for testing novel approaches to treatment. In the case of genetic disorders, once the 
chromosomal loci are determined along with the pattern of inheritance, a transgenic system 
can be generated to model the different aspects of the disease. The transgenic systems have 
immense importance for understanding the pathophysiological basis of disorders that could 
mimic the human counterpart. These transgenic model organisms aid in identifying the 
cellular and molecular mechanisms responsible for disease phenotypes. They also provide a 
platform on which the efficacy and side effects of potential drug treatments can be evaluated. 
The development of PD genetic models holds tremendous potential for the testing of novel 
approaches.   
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CONCLUSIONS 
A better understanding of the pathophysiology of PD is only possible with the development 
of reliable experimental models that can mimic disease processes with good reliability. A 
large number of animal models of PD have now been developed, and they have 
revolutionized PD research. Understanding of the etiology, pathogenesis, and molecular 
mechanisms of PD has improved, and new potential therapeutics have emerged. While 
cellular models have helped to identify specific events and signaling cascades, animal 
models, both toxin-based and genetic, have replicated almost all of the hallmarks of PD and 
are useful for testing new neuroprotective or neurorestorative strategies. The zebrafish, with a 
vertebrate biology and with easy methods of genetic manipulation, has become more feasible 
for research and comparable to mammals than invertebrate models. 
Overall, the results in this work provided novel insights into the function of pink1. The main 
conclusions that can be drawn from this study are as follows: 
1. The development of the catecholaminergic system in zebrafish has now been well 
characterized. The identification in zebrafish of a second non-allelic gene, th2, which has a 
complementary expression to th1, adds a new dimension to the future analysis of brain 
functions in this species. A lack of pink1 significantly affects both the th1 and th2 transcripts. 
This is consistent with human PD patients, in whom nigral dopaminergic cell loss occurs. 
2. A lack of pink1 sensitizes the fish to sub-effective doses of MPTP. The loss of TH-ir was 
observed in the pre-tectum and vDC group (5,6,11). Major changes were observed in the two 
th transcripts. Both th1 and th2 were significantly downregulated. No significant change in 
the dat or hdc transcripts was observed in the pink1 morphants. The effects of both forms of 
th could be rescued by injection with pink1 mRNA, suggesting specific roles for pink1 in the 
development of these neurons. Pink1-ir was detected in most parts of the brain, and the data 
were in agreement with the in situ pink1 mRNA. 
3. The gene list obtained by the microarray data analysis was validated by Q-RT-PCR. Using 
a commercial pathway analysis program, potentially important pathways were mapped. This 
revealed that the most important pathway was HIF signaling.  
4. Using independent assays, the HIF targets such as VEGF, erythropoiesis, ROS, and notch 
were analyzed in the pink1 morphants. VEGF transcripts were altered in the pink1 morphants. 
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Vegfaa and vegfab, which are important for angiogenesis, were upregulated, while the other 
forms of vegfs were unaltered. Erythropoiesis was increased in the morphants, which could 
be rescued by the addition of antioxidants such as LGR and NAC. An increase in ROS and 
notch1a was also observed, and these were rescued by the injection of pink1 mRNA. The 
observed decrease in cat, sod2, and prdx3 transcript levels together with catalase activity 
suggests that due to the lack of pink1, the essential antioxidative enzyme systems were also 
compromised. 
5.  The pink1 transgenic fish line was created using a promoter construct at -2 kb upstream of 
the translation start site. The GFP expression completely colocalized with the PINK1-ir. 
When the Tg(pink1:EGFP) fish were subjected to a very low dose of H2O2, an increase in the 
expression of the transgene was observed in the brain of the larval fish. This effect could be 
reversed by the addition of the antioxidant LGR. These findings indicate the development of 
a new tool to analyze pink1 regulation under conditions relevant for disease mechanisms. 
The mechanisms of these novel-signaling pathways would help in improvement of potential 
therapeutic targets for attenuation of the cardinal symptoms and motor complications in 
patients with Pink1 deficiency or PD as whole in the future. 
 
Figure 6. A schematic diagram representing the data generated from the pink1 knockdown 
studies using MO in zebrafish. Pink1 dysfunction affects the function of HIF. The targets of 
HIF are also altered in the morphants, concluding that HIF-mediated neuroprotective 
strategies could be important for the development of effective therapies to mitigate or prevent 
PD.  
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